[
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "topical irrigation with the antibiotic bacitracin",
		"description" : "Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure.",
		"intervention_name" : "topical irrigation with the antibiotic bacitracin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>topical irrigation with the antibiotic bacitracin</intervention_name>\n    <description>Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure.</description>\n    <arm_group_label>topical irrigation with the antibiotic bacitracin</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "topical irrigation with sterile normal saline (NS)",
		"description" : "Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.",
		"intervention_name" : "topical irrigation with sterile normal saline (NS)",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>topical irrigation with sterile normal saline (NS)</intervention_name>\n    <description>Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.</description>\n    <arm_group_label>topical irrigation with sterile normal saline (NS)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sof+Velpa+R+Peg-IFN arm",
		"description" : "Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week",
		"intervention_name" : "Sof+Velpa+R+Peg-IFN arm",
		"intervention_type" : "Drug",
		"other_name" : "SVR+Peg",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sof+Velpa+R+Peg-IFN arm</intervention_name>\n    <description>Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight =&gt;75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week</description>\n    <arm_group_label>Sof+Velpa+R+Peg-IFN arm</arm_group_label>\n    <other_name>SVR+Peg</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "SHR6390 combined with pyrotinib",
		"description" : "SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer",
		"intervention_name" : "SHR6390",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>SHR6390</intervention_name>\n    <description>SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer</description>\n    <arm_group_label>SHR6390 combined with pyrotinib</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sof+Dacla+R+Peg-IFN arm",
		"description" : "Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week",
		"intervention_name" : "Sof+Dacla+R+Peg-IFN arm",
		"intervention_type" : "Drug",
		"other_name" : "SDR+Peg",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sof+Dacla+R+Peg-IFN arm</intervention_name>\n    <description>Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight =&gt;75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week</description>\n    <arm_group_label>Sof+Dacla+R+Peg-IFN arm</arm_group_label>\n    <other_name>SDR+Peg</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sof+Velpa+R arm",
		"description" : "Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses",
		"intervention_name" : "Sof+Velpa+R arm",
		"intervention_type" : "Drug",
		"other_name" : "SVR",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sof+Velpa+R arm</intervention_name>\n    <description>Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight =&gt;75 kg) daily in two divided doses</description>\n    <arm_group_label>Sof+Velpa+R arm</arm_group_label>\n    <other_name>SVR</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sof+Ledi+R+Peg-IFN arm",
		"description" : "Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week",
		"intervention_name" : "Sof+Ledi+R+Peg-IFN arm",
		"intervention_type" : "Drug",
		"other_name" : "SLR+Peg",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sof+Ledi+R+Peg-IFN arm</intervention_name>\n    <description>Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight =&gt;75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week</description>\n    <arm_group_label>Sof+Ledi+R+Peg-IFN arm</arm_group_label>\n    <other_name>SLR+Peg</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sof+Dacla+R arm",
		"description" : "Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses",
		"intervention_name" : "Sof+Dacla+R arm",
		"intervention_type" : "Drug",
		"other_name" : "SDR",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sof+Dacla+R arm</intervention_name>\n    <description>Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight =&gt;75 kg) daily in two divided doses</description>\n    <arm_group_label>Sof+Dacla+R arm</arm_group_label>\n    <other_name>SDR</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Padsevonil and Erythromycin",
		"description" : "Pharmaceutical Form: film-coated tablet\nRoute of Administration: Oral use",
		"intervention_name" : "Erythromycin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Erythromycin</intervention_name>\n    <description>Pharmaceutical Form: film-coated tablet\nRoute of Administration: Oral use</description>\n    <arm_group_label>Padsevonil and Erythromycin</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.47",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sof+Ledi+R arm",
		"description" : "Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses",
		"intervention_name" : "Sof+Ledi+R arm",
		"intervention_type" : "Drug",
		"other_name" : "SLR",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sof+Ledi+R arm</intervention_name>\n    <description>Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight =&gt;75 kg) daily in two divided doses</description>\n    <arm_group_label>Sof+Ledi+R arm</arm_group_label>\n    <other_name>SLR</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Grup L",
		"description" : "Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine",
		"intervention_name" : "Bupivacaine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Bupivacaine</intervention_name>\n    <description>Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine</description>\n    <arm_group_label>Grup L</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Administered orally",
		"intervention_name" : "CPI-1205",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>CPI-1205</intervention_name>\n    <description>Administered orally</description>\n    <arm_group_label>CPI-1205 Combination with Enzalutamide</arm_group_label>\n    <arm_group_label>CPI-1205 Combination with Abiraterone/Prednisone</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .",
		"intervention_name" : "Heparin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Heparin</intervention_name>\n    <description>Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &amp;warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .</description>\n    <arm_group_label>MVT with anticoagulation therapy(heparin &amp;warfarin)</arm_group_label>\n    <arm_group_label>MVT with failure of anticoagulation therapy(heparin &amp;warfarin)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.",
		"intervention_name" : "Morphine Sulfate",
		"intervention_type" : "Drug",
		"other_name" : "Morphine",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Morphine Sulfate</intervention_name>\n    <description>Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.</description>\n    <arm_group_label>Grup L</arm_group_label>\n    <arm_group_label>Group P</arm_group_label>\n    <other_name>Morphine</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .",
		"intervention_name" : "Warfarin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Warfarin</intervention_name>\n    <description>Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &amp;warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .</description>\n    <arm_group_label>MVT with anticoagulation therapy(heparin &amp;warfarin)</arm_group_label>\n    <arm_group_label>MVT with failure of anticoagulation therapy(heparin &amp;warfarin)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then\" second look\" laparotomy will be performed .The mortality and all complications associated with surgery will be recorded.",
		"intervention_name" : "MVT with failure of anticoagulation therapy",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>MVT with failure of anticoagulation therapy</intervention_name>\n    <description>patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then\" second look\" laparotomy will be performed .The mortality and all complications associated with surgery will be recorded.</description>\n    <arm_group_label>MVT with anticoagulation therapy(heparin &amp;warfarin)</arm_group_label>\n    <arm_group_label>MVT with failure of anticoagulation therapy(heparin &amp;warfarin)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "HA0.4%+TAU0.5%",
		"description" : "4 drops /day in addition to the ongoing glaucoma treatment",
		"intervention_name" : "Hyaluronic acid 0.4% and Taurine 0.5%",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Hyaluronic acid 0.4% and Taurine 0.5%</intervention_name>\n    <description>4 drops /day in addition to the ongoing glaucoma treatment</description>\n    <arm_group_label>HA0.4%+TAU0.5%</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "HA0.2%",
		"description" : "4 drops /day in addition to the ongoing glaucoma treatment",
		"intervention_name" : "Hyaluronic acid 0.2%",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Hyaluronic acid 0.2%</intervention_name>\n    <description>4 drops /day in addition to the ongoing glaucoma treatment</description>\n    <arm_group_label>HA0.2%</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Wellness Group",
		"intervention_name" : "Wellness Group",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Wellness Group</intervention_name>\n    <arm_group_label>Wellness Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "AstroRx",
		"description" : "Astrocytes derived from human embryonic stem cells",
		"intervention_name" : "AstroRx",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>AstroRx</intervention_name>\n    <description>Astrocytes derived from human embryonic stem cells</description>\n    <arm_group_label>AstroRx</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Single Arm",
		"description" : "Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being",
		"intervention_name" : "Multi-Disciplinary Patient Centered Rehab and Education",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Multi-Disciplinary Patient Centered Rehab and Education</intervention_name>\n    <description>Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being</description>\n    <arm_group_label>Single Arm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Mindfulness-based stress reduction",
		"intervention_name" : "Mindfulness-based stress reduction",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Mindfulness-based stress reduction</intervention_name>\n    <arm_group_label>Mindfulness-based stress reduction</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.\nThe pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.\nPleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.\nc-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.\nPleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion.",
		"intervention_name" : "Pleural fluid C-reactive protein",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Pleural fluid C-reactive protein</intervention_name>\n    <description>C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.\nThe pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.\nPleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.\nc-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.\nPleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion.</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.21",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention group",
		"description" : "Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.",
		"intervention_name" : "Intervention group",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Intervention group</intervention_name>\n    <description>Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.</description>\n    <arm_group_label>Intervention group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PMR 150 mg",
		"description" : "Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)",
		"intervention_name" : "PMR 150 mg",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>PMR 150 mg</intervention_name>\n    <description>Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)</description>\n    <arm_group_label>PMR 150 mg</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PMR 200 mg",
		"description" : "Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)",
		"intervention_name" : "PMR 200 mg",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>PMR 200 mg</intervention_name>\n    <description>Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)</description>\n    <arm_group_label>PMR 200 mg</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Liposomal irinotecan with FOLFOX",
		"description" : "Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.",
		"intervention_name" : "FOLFOX regimen",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>FOLFOX regimen</intervention_name>\n    <description>Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.</description>\n    <arm_group_label>Liposomal irinotecan with FOLFOX</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Padsevonil and Erythromycin",
		"description" : "Pharmaceutical Form: film-coated tablet\nRoute of Administration: Oral use",
		"intervention_name" : "Padsevonil (UCB0942)",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Padsevonil (UCB0942)</intervention_name>\n    <description>Pharmaceutical Form: film-coated tablet\nRoute of Administration: Oral use</description>\n    <arm_group_label>Padsevonil and Erythromycin</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.46",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "Placebo oral table twice daily for 3 days prior to experimental testing",
		"intervention_name" : "Placebo Oral Tablet",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo Oral Tablet</intervention_name>\n    <description>Placebo oral table twice daily for 3 days prior to experimental testing</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Liposomal irinotecan with FOLFOX",
		"description" : "Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.",
		"intervention_name" : "Liposomal Irinotecan",
		"intervention_type" : "Drug",
		"other_name" : "ONIVYDE",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Liposomal Irinotecan</intervention_name>\n    <description>Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.</description>\n    <arm_group_label>Liposomal irinotecan with FOLFOX</arm_group_label>\n    <other_name>ONIVYDE</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort",
		"intervention_name" : "Collection of a Pharmaceutical Intervertion",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Collection of a Pharmaceutical Intervertion</intervention_name>\n    <description>collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort</description>\n    <arm_group_label>Primary cohort</arm_group_label>\n    <arm_group_label>Secondary cohort</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Salsalate",
		"description" : "2250mg twice daily for 3 days prior to experimental testing",
		"intervention_name" : "Salsalate Oral Tablet",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Salsalate Oral Tablet</intervention_name>\n    <description>2250mg twice daily for 3 days prior to experimental testing</description>\n    <arm_group_label>Salsalate</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Parent Coaches",
		"description" : "Online and in-person training and weekly supervision with licensed clinical social worker while delivering the \"Family Check-Up\" to 5 families.",
		"intervention_name" : "Interventionist training and supervision",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Interventionist training and supervision</intervention_name>\n    <description>Online and in-person training and weekly supervision with licensed clinical social worker while delivering the \"Family Check-Up\" to 5 families.</description>\n    <arm_group_label>Parent Coaches</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Parent-Child Dyads",
		"description" : "Up to 6 sessions of the \"Family Check-Up\" program, involving discussions, assessments, feedback, and skills training with a parent coach.",
		"intervention_name" : "Behavioral parent training",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Behavioral parent training</intervention_name>\n    <description>Up to 6 sessions of the \"Family Check-Up\" program, involving discussions, assessments, feedback, and skills training with a parent coach.</description>\n    <arm_group_label>Parent-Child Dyads</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Pharyngeal Electrical Stimulation",
		"description" : "Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.",
		"intervention_name" : "Pharyngeal Electrical Stimulation",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Pharyngeal Electrical Stimulation</intervention_name>\n    <description>Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.</description>\n    <arm_group_label>Pharyngeal Electrical Stimulation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "autonomic function testing, ergospirometry, three questionnaires\nOther Names:\nThe autonomic function tests consist of five tests:\nThe Valsalva maneuver\nThe isometric handgrip test\nThe deep breathing test\nThe cold pressor test\nA short head-up tilt test\nA maximal ergospirometry\nThree questionnaires:\nEQ-5D-3L: quality of life\nIPAQ: capacity to do physical activities",
		"intervention_name" : "autonomic function testing",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>autonomic function testing</intervention_name>\n    <description>autonomic function testing, ergospirometry, three questionnaires\nOther Names:\nThe autonomic function tests consist of five tests:\nThe Valsalva maneuver\nThe isometric handgrip test\nThe deep breathing test\nThe cold pressor test\nA short head-up tilt test\nA maximal ergospirometry\nThree questionnaires:\nEQ-5D-3L: quality of life\nIPAQ: capacity to do physical activities</description>\n    <arm_group_label>subjects with Type 1 Diabetes mellitus</arm_group_label>\n    <arm_group_label>Healthy controls</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Google Cardboard VRA",
		"description" : "Intervention was randomized and shuffled.",
		"intervention_name" : "Google Cardboard VRA",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Google Cardboard VRA</intervention_name>\n    <description>Intervention was randomized and shuffled.</description>\n    <arm_group_label>Google Cardboard VRA</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Oculus Rift VRA",
		"description" : "Intervention was randomized and shuffled.",
		"intervention_name" : "Oculus Rift VRA",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Oculus Rift VRA</intervention_name>\n    <description>Intervention was randomized and shuffled.</description>\n    <arm_group_label>Oculus Rift VRA</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Bupivacaine",
		"intervention_name" : "Bupivacaine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Bupivacaine</intervention_name>\n    <description>Bupivacaine</description>\n    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>\n    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>\n    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural \"r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used.",
		"intervention_name" : "HRC-test",
		"intervention_type" : "Genetic",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Genetic</intervention_type>\n    <intervention_name>HRC-test</intervention_name>\n    <description>Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural \"r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used.</description>\n    <arm_group_label>FS: Febrile Seizures</arm_group_label>\n    <arm_group_label>CN: Control group</arm_group_label>\n    <arm_group_label>SFS : group of individuals with simple FS</arm_group_label>\n    <arm_group_label>CFS : group of individuals with complex FS</arm_group_label>\n    <arm_group_label>WFS: group of individuals with FS and without epilepsia</arm_group_label>\n    <arm_group_label>EFS: group of individuals with epilepsia and Febrile Seizures</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block",
		"intervention_name" : "Fentanyl",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Fentanyl</intervention_name>\n    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block</description>\n    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>\n    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block",
		"intervention_name" : "Dexamethasone",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dexamethasone</intervention_name>\n    <description>Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block</description>\n    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>\n    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Fall Monty Activity Programme (FallMAP)",
		"description" : "The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing & falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.",
		"intervention_name" : "Fall Monty Activity Programme (FallMAP)",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Fall Monty Activity Programme (FallMAP)</intervention_name>\n    <description>The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing &amp; falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.</description>\n    <arm_group_label>Fall Monty Activity Programme (FallMAP)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cilostazol 100 mg",
		"description" : "One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)",
		"intervention_name" : "Cilostazol 100 mg",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Cilostazol 100 mg</intervention_name>\n    <description>One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)</description>\n    <arm_group_label>Cilostazol 100 mg</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Ablation therapy for cardiac arrhythmias",
		"intervention_name" : "Ablation",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Ablation</intervention_name>\n    <description>Ablation therapy for cardiac arrhythmias</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PEXG treated with MLT",
		"description" : "Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.",
		"intervention_name" : "Micropulse laser trabeculoplasty",
		"intervention_type" : "Procedure",
		"other_name" : "MLT Iridex IQ 532 laser system",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Micropulse laser trabeculoplasty</intervention_name>\n    <description>Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.</description>\n    <arm_group_label>PEXG treated with MLT</arm_group_label>\n    <other_name>MLT Iridex IQ 532 laser system</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Atezolizumab + Stereotactic radiosurgery (SRS)",
		"description" : "Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors",
		"intervention_name" : "Stereotactic radiosurgery (SRS)",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Stereotactic radiosurgery (SRS)</intervention_name>\n    <description>Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors</description>\n    <arm_group_label>Atezolizumab + Stereotactic radiosurgery (SRS)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Prognosis Information and Provider Scripts",
		"description" : "An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.",
		"intervention_name" : "Prognosis information and Provider Scripts",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Prognosis information and Provider Scripts</intervention_name>\n    <description>An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.</description>\n    <arm_group_label>Prognosis Information and Provider Scripts</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "BioFe Medical Food",
		"description" : "BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried",
		"intervention_name" : "BioFe",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>BioFe</intervention_name>\n    <description>BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried</description>\n    <arm_group_label>BioFe Medical Food</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Atezolizumab + Stereotactic radiosurgery (SRS)",
		"description" : "Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway",
		"intervention_name" : "Atezolizumab",
		"intervention_type" : "Drug",
		"other_name" : "Tecentriq",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Atezolizumab</intervention_name>\n    <description>Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway</description>\n    <arm_group_label>Atezolizumab + Stereotactic radiosurgery (SRS)</arm_group_label>\n    <other_name>Tecentriq</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "ESP group",
		"description" : "erector spinae plane block will be administered before the surgery",
		"intervention_name" : "Erector Spinae Plane Block",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Erector Spinae Plane Block</intervention_name>\n    <description>erector spinae plane block will be administered before the surgery</description>\n    <arm_group_label>ESP group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "TPVB group",
		"description" : "thoracic paravertebral block will be administered before the surgery",
		"intervention_name" : "Thoracic Paravertebral Block",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Thoracic Paravertebral Block</intervention_name>\n    <description>thoracic paravertebral block will be administered before the surgery</description>\n    <arm_group_label>TPVB group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.",
		"intervention_name" : "Hematopoietic Stem Cell Transplant",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Hematopoietic Stem Cell Transplant</intervention_name>\n    <description>Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.</description>\n    <arm_group_label>With Malglycemia</arm_group_label>\n    <arm_group_label>Without Malglycemia</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "24 hour morphine consumption will be recorded",
		"intervention_name" : "Intravenous morphine patient controlled device",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Intravenous morphine patient controlled device</intervention_name>\n    <description>24 hour morphine consumption will be recorded</description>\n    <arm_group_label>ESP group</arm_group_label>\n    <arm_group_label>TPVB group</arm_group_label>\n    <arm_group_label>Control Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "right IPL cTBS",
		"description" : "15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4",
		"intervention_name" : "right IPL cTBS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>right IPL cTBS</intervention_name>\n    <description>15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4</description>\n    <arm_group_label>right IPL cTBS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "placebo",
		"description" : "rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL",
		"intervention_name" : "Placebo",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL</description>\n    <arm_group_label>placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Microwave energy treatment",
		"description" : "Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.",
		"intervention_name" : "Microwave treatment",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Microwave treatment</intervention_name>\n    <description>Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.</description>\n    <arm_group_label>Microwave energy treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "left IFG iTBS",
		"description" : "15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4",
		"intervention_name" : "left IFG iTBS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>left IFG iTBS</intervention_name>\n    <description>15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4</description>\n    <arm_group_label>left IFG iTBS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm A",
		"description" : "Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.",
		"intervention_name" : "Nivolumab plus radiotherapy",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Nivolumab plus radiotherapy</intervention_name>\n    <description>Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.</description>\n    <arm_group_label>Arm A</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single \"On/Off\" switch. It will be attached to a rolling stand.\nThis light is fitted with a blue spectrum filter (peak 441 nm) such that it produces 1000 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject.",
		"intervention_name" : "Blue Light",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Blue Light</intervention_name>\n    <description>Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single \"On/Off\" switch. It will be attached to a rolling stand.\nThis light is fitted with a blue spectrum filter (peak 441 nm) such that it produces 1000 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject.</description>\n    <arm_group_label>Pneumonia: Blue Light</arm_group_label>\n    <arm_group_label>Diverticulitis: Blue Light</arm_group_label>\n    <arm_group_label>Appendicitis: Blue Light</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Pregabalin Group",
		"description" : "pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.",
		"intervention_name" : "Pragabalin",
		"intervention_type" : "Drug",
		"other_name" : "pregabalin 150 mg, Lyrica, Pfezir, Almanya",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Pragabalin</intervention_name>\n    <description>pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.</description>\n    <arm_group_label>Pregabalin Group</arm_group_label>\n    <other_name>pregabalin 150 mg, Lyrica, Pfezir, Almanya</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control Group",
		"description" : "empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"other_name" : "empty capsule",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.</description>\n    <arm_group_label>Control Group</arm_group_label>\n    <other_name>empty capsule</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 2, 4, 6, 9, and 12-months following end of chemoradiation",
		"intervention_name" : "Patient-Reported Outcome Measures",
		"intervention_type" : "Other",
		"other_name" : "PROs",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Patient-Reported Outcome Measures</intervention_name>\n    <description>-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 2, 4, 6, 9, and 12-months following end of chemoradiation</description>\n    <arm_group_label>Arm 1: Resectable (proton beam therapy)</arm_group_label>\n    <arm_group_label>Arm 2: Unresectable (proton beam therapy)</arm_group_label>\n    <other_name>PROs</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Daylight Intervention",
		"description" : "Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.",
		"intervention_name" : "Daylight Intervention",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Daylight Intervention</intervention_name>\n    <description>Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.</description>\n    <arm_group_label>Daylight Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.",
		"intervention_name" : "Molgramostim",
		"intervention_type" : "Drug",
		"other_name" : "Recombinant human GM-CSF",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Molgramostim</intervention_name>\n    <description>300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.</description>\n    <other_name>Recombinant human GM-CSF</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "-The daily prescription dose will be 2 Gy RBE (\"Relative Biologic Equivalence\") to be delivered to the periphery of the planning target volume (PTV).",
		"intervention_name" : "Proton beam therapy",
		"intervention_type" : "Radiation",
		"other_name" : "PBT",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>Proton beam therapy</intervention_name>\n    <description>-The daily prescription dose will be 2 Gy RBE (\"Relative Biologic Equivalence\") to be delivered to the periphery of the planning target volume (PTV).</description>\n    <arm_group_label>Arm 1: Resectable (proton beam therapy)</arm_group_label>\n    <arm_group_label>Arm 2: Unresectable (proton beam therapy)</arm_group_label>\n    <other_name>PBT</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Single Arm",
		"description" : "Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks",
		"intervention_name" : "Gemcitabine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Gemcitabine</intervention_name>\n    <description>Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks</description>\n    <arm_group_label>Single Arm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Consultation",
		"description" : "15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.",
		"intervention_name" : "Consultation",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Consultation</intervention_name>\n    <description>15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.</description>\n    <arm_group_label>Consultation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):\nleft-excitatory tDCS (N=20)\nright-inhibitory tDCS (N=20)\nsham tDCS (N=20)\n4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS\n2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS",
		"intervention_name" : "Transcranial stimulation",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Transcranial stimulation</intervention_name>\n    <description>10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):\nleft-excitatory tDCS (N=20)\nright-inhibitory tDCS (N=20)\nsham tDCS (N=20)\n4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS\n2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS</description>\n    <arm_group_label>1:left-excitatory tDCS</arm_group_label>\n    <arm_group_label>2:right-inhibitory tDCS</arm_group_label>\n    <arm_group_label>3:sham tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Single Arm",
		"description" : "Avelumab IV 10 mg/kg every 2 weeks",
		"intervention_name" : "Avelumab",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Avelumab</intervention_name>\n    <description>Avelumab IV 10 mg/kg every 2 weeks</description>\n    <arm_group_label>Single Arm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.",
		"intervention_name" : "Daptomycin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Daptomycin</intervention_name>\n    <description>Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment",
		"description" : "lisocabtagene maraleucel",
		"intervention_name" : "lisocabtagene maraleucel",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>lisocabtagene maraleucel</intervention_name>\n    <description>lisocabtagene maraleucel</description>\n    <arm_group_label>Treatment</arm_group_label>\n    <other_name>JCAR017</other_name>\n    <other_name>liso-cel</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "2",
		"description" : "For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.",
		"intervention_name" : "Dummy Packaging",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Dummy Packaging</intervention_name>\n    <description>For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.</description>\n    <arm_group_label>2</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "We will be randomizing across providers - we are particularly interested in racial concordance.",
		"intervention_name" : "Concordant",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Concordant</intervention_name>\n    <description>We will be randomizing across providers - we are particularly interested in racial concordance.</description>\n    <arm_group_label>Discordant</arm_group_label>\n    <arm_group_label>Concordant</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Replenish Protein group",
		"description" : "Subjects randomized to this group will receive 2 g of protein/kg/day of added protein supplement, which is the Beneprotein targeting acceptable range for this group as 1.8 - 2.2 g of protein/kg/day for day 6-14.",
		"intervention_name" : "Replenish Protein",
		"intervention_type" : "Dietary Supplement",
		"other_name" : "Intervention group",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Replenish Protein</intervention_name>\n    <description>Subjects randomized to this group will receive 2 g of protein/kg/day of added protein supplement, which is the Beneprotein targeting acceptable range for this group as 1.8 - 2.2 g of protein/kg/day for day 6-14.</description>\n    <arm_group_label>Replenish Protein group</arm_group_label>\n    <other_name>Intervention group</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Standard Protein group",
		"description" : "The subjects randomized to this group will receive protein at 0.8 - 1.0 g of protein/kg/day for day 6-14",
		"intervention_name" : "Standard protein",
		"intervention_type" : "Dietary Supplement",
		"other_name" : "Control group",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Standard protein</intervention_name>\n    <description>The subjects randomized to this group will receive protein at 0.8 - 1.0 g of protein/kg/day for day 6-14</description>\n    <arm_group_label>Standard Protein group</arm_group_label>\n    <other_name>Control group</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "WES",
		"description" : "The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.",
		"intervention_name" : "Whole Exome Sequencing (WES)",
		"intervention_type" : "Genetic",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Genetic</intervention_type>\n    <intervention_name>Whole Exome Sequencing (WES)</intervention_name>\n    <description>The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.</description>\n    <arm_group_label>WES</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "alirocumab",
		"description" : "Cholesterol-lowering therapy",
		"intervention_name" : "Alirocumab 150 MG/ML [Praluent]",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Alirocumab 150 MG/ML [Praluent]</intervention_name>\n    <description>Cholesterol-lowering therapy</description>\n    <arm_group_label>alirocumab</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Active 600 mg Tempol Solution",
		"description" : "Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.",
		"intervention_name" : "Tempol",
		"intervention_type" : "Drug",
		"other_name" : "4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Tempol</intervention_name>\n    <description>Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.</description>\n    <arm_group_label>Active 600 mg Tempol Solution</arm_group_label>\n    <other_name>4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo Solution",
		"description" : "The placebo contains the same excipients as the active product plus FD&C Yellow #6 for color matching.",
		"intervention_name" : "Placebo Solution",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo Solution</intervention_name>\n    <description>The placebo contains the same excipients as the active product plus FD&amp;C Yellow #6 for color matching.</description>\n    <arm_group_label>Placebo Solution</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Hyperpolarized Xenon gas\nHyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)\nAdministration: By mouthpiece attached to a single use Tedlar bag.\nDosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.\nFrequency: 10-minute interval between doses.",
		"intervention_name" : "Hyperpolarized Xenon gas",
		"intervention_type" : "Drug",
		"other_name" : "129Xe",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Hyperpolarized Xenon gas</intervention_name>\n    <description>Hyperpolarized Xenon gas\nHyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)\nAdministration: By mouthpiece attached to a single use Tedlar bag.\nDosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.\nFrequency: 10-minute interval between doses.</description>\n    <arm_group_label>129Xe MRI followed by 19F MRI with PFP</arm_group_label>\n    <arm_group_label>19F MRI with PFP followed by 129Xe MRI</arm_group_label>\n    <other_name>129Xe</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)\nAdministration: Full-face disposable ventilation mask and a standard Douglas Bag system.\nDosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.\nFrequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.",
		"intervention_name" : "PFP",
		"intervention_type" : "Drug",
		"other_name" : "Perfluoropropane gas (C3F8); 19F",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>PFP</intervention_name>\n    <description>Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)\nAdministration: Full-face disposable ventilation mask and a standard Douglas Bag system.\nDosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.\nFrequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.</description>\n    <arm_group_label>129Xe MRI followed by 19F MRI with PFP</arm_group_label>\n    <arm_group_label>19F MRI with PFP followed by 129Xe MRI</arm_group_label>\n    <other_name>Perfluoropropane gas (C3F8); 19F</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "hypertensive patients",
		"description" : "device used for measurement of brachial blood pressure",
		"intervention_name" : "sphygmomanometer",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>sphygmomanometer</intervention_name>\n    <description>device used for measurement of brachial blood pressure</description>\n    <arm_group_label>hypertensive patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "hypertensive patients",
		"description" : "device used for measurement of central blood pressure",
		"intervention_name" : "mobilogragh",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>mobilogragh</intervention_name>\n    <description>device used for measurement of central blood pressure</description>\n    <arm_group_label>hypertensive patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Responsive parenting treatment",
		"description" : "Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with your baby",
		"intervention_name" : "Responsive parenting curriculum",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Responsive parenting curriculum</intervention_name>\n    <description>Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with your baby</description>\n    <arm_group_label>Responsive parenting treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Responsive parenting treatment",
		"description" : "Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.",
		"intervention_name" : "Data sharing/coordination",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Data sharing/coordination</intervention_name>\n    <description>Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.</description>\n    <arm_group_label>Responsive parenting treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "Placebo (film-coated tablet) matching gefapixant to be administered orally BID",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Placebo (film-coated tablet) matching gefapixant to be administered orally BID</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Responsive parenting treatment",
		"description" : "Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future",
		"intervention_name" : "Early healthy lifestyles",
		"intervention_type" : "Behavioral",
		"other_name" : "EHL",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Early healthy lifestyles</intervention_name>\n    <description>Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future</description>\n    <arm_group_label>Responsive parenting treatment</arm_group_label>\n    <other_name>EHL</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Epidural injection for the relief of back pain",
		"intervention_name" : "Epidural injection",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Epidural injection</intervention_name>\n    <description>Epidural injection for the relief of back pain</description>\n    <arm_group_label>Shen Men acupuncture</arm_group_label>\n    <arm_group_label>Sham acupuncture</arm_group_label>\n    <arm_group_label>Simulated acupuncture</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Gefapixant 45 mg",
		"description" : "Gefapixant 45 mg (film-coated tablet) to be administered orally BID",
		"intervention_name" : "Gefapixant 45 mg",
		"intervention_type" : "Drug",
		"other_name" : "MK-7264",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Gefapixant 45 mg</intervention_name>\n    <description>Gefapixant 45 mg (film-coated tablet) to be administered orally BID</description>\n    <arm_group_label>Gefapixant 45 mg</arm_group_label>\n    <other_name>MK-7264</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment",
		"intervention_name" : "SHR6390",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>SHR6390</intervention_name>\n    <description>SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment</description>\n    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>\n    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>\n    <arm_group_label>SHR6390 + Letrozole (Part 2)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Letrozole, 2.5mg, orally once daily (continuously)",
		"intervention_name" : "Letrozole",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Letrozole</intervention_name>\n    <description>Letrozole, 2.5mg, orally once daily (continuously)</description>\n    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>\n    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>\n    <arm_group_label>SHR6390 + Letrozole (Part 2)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Virtual Reality",
		"description" : "Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy",
		"intervention_name" : "Virtual Reality",
		"intervention_type" : "Device",
		"other_name" : "Bliss",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Virtual Reality</intervention_name>\n    <description>Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy</description>\n    <arm_group_label>Virtual Reality</arm_group_label>\n    <other_name>Bliss</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Kalinox®",
		"description" : "Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)",
		"intervention_name" : "Kalinox",
		"intervention_type" : "Drug",
		"other_name" : "Control",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Kalinox</intervention_name>\n    <description>Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)</description>\n    <arm_group_label>Kalinox®</arm_group_label>\n    <other_name>Control</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Methylphenidate",
		"description" : "Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).\nThis gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).",
		"intervention_name" : "Methylphenidate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Methylphenidate</intervention_name>\n    <description>Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).\nThis gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).</description>\n    <arm_group_label>Methylphenidate</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Matching Placebo",
		"description" : "Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).\nThis gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).",
		"intervention_name" : "Matching Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Matching Placebo</intervention_name>\n    <description>Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).\nThis gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).</description>\n    <arm_group_label>Matching Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "hypertensive patients",
		"description" : "Electrocardiogram",
		"intervention_name" : "ECG",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>ECG</intervention_name>\n    <description>Electrocardiogram</description>\n    <arm_group_label>hypertensive patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "hypertensive patients",
		"description" : "Echocardiography",
		"intervention_name" : "Echocardiography",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Echocardiography</intervention_name>\n    <description>Echocardiography</description>\n    <arm_group_label>hypertensive patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Vasopressin group",
		"description" : "Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.\nContinuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min",
		"intervention_name" : "Vasopressin",
		"intervention_type" : "Drug",
		"other_name" : "Blinded Vasopressin",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Vasopressin</intervention_name>\n    <description>Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement.\nContinuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min</description>\n    <arm_group_label>Vasopressin group</arm_group_label>\n    <other_name>Blinded Vasopressin</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Norepinephrine group",
		"description" : "Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.",
		"intervention_name" : "Norepinephrine",
		"intervention_type" : "Drug",
		"other_name" : "Blinded Norepinephrine",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Norepinephrine</intervention_name>\n    <description>Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.</description>\n    <arm_group_label>Norepinephrine group</arm_group_label>\n    <other_name>Blinded Norepinephrine</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM & JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient",
		"intervention_name" : "Physical therapy",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Physical therapy</intervention_name>\n    <description>The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM &amp; JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient</description>\n    <arm_group_label>Experimental: hf rTMS and Physical therapy</arm_group_label>\n    <arm_group_label>Control: Sham hf rTMS and Physical theraphy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement",
		"intervention_name" : "Online Mindfulness Based Cancer Recovery (MBCR)",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Online Mindfulness Based Cancer Recovery (MBCR)</intervention_name>\n    <description>MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement</description>\n    <arm_group_label>Immediate MBCR group</arm_group_label>\n    <arm_group_label>Waitlist control group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arthritis or lupus or CLS induced by a drug",
		"description" : "Drugs susceptible to induce arthritis, lupus or capillary leak syndrom",
		"intervention_name" : "drug inducing arthritis, lupus or capillary leak syndrom",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>drug inducing arthritis, lupus or capillary leak syndrom</intervention_name>\n    <description>Drugs susceptible to induce arthritis, lupus or capillary leak syndrom</description>\n    <arm_group_label>Arthritis or lupus or CLS induced by a drug</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.",
		"intervention_name" : "TMS",
		"intervention_type" : "Device",
		"other_name" : "non invasive brain stimulation, high frequency rTMS",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>TMS</intervention_name>\n    <description>Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.</description>\n    <arm_group_label>Experimental: hf rTMS and Physical therapy</arm_group_label>\n    <arm_group_label>Control: Sham hf rTMS and Physical theraphy</arm_group_label>\n    <other_name>non invasive brain stimulation, high frequency rTMS</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Adjuvanted formulation includes Alhydrogel",
		"intervention_name" : "CHIKV VLP/adjuvanted",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>CHIKV VLP/adjuvanted</intervention_name>\n    <description>Adjuvanted formulation includes Alhydrogel</description>\n    <arm_group_label>Arm 2</arm_group_label>\n    <arm_group_label>Arm 3</arm_group_label>\n    <arm_group_label>Arm 4</arm_group_label>\n    <arm_group_label>Arm 5</arm_group_label>\n    <arm_group_label>Arm 6</arm_group_label>\n    <arm_group_label>Arm 7</arm_group_label>\n    <arm_group_label>Arm 8</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Placebo is vaccine diluent alone",
		"intervention_name" : "Placebo",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Placebo is vaccine diluent alone</description>\n    <arm_group_label>Arm 1</arm_group_label>\n    <arm_group_label>Arm 2</arm_group_label>\n    <arm_group_label>Arm 3</arm_group_label>\n    <arm_group_label>Arm 4</arm_group_label>\n    <arm_group_label>Arm 5</arm_group_label>\n    <arm_group_label>Arm 6</arm_group_label>\n    <arm_group_label>Arm 7</arm_group_label>\n    <arm_group_label>Arm 8</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Follitropin delta and HP-hMG",
		"description" : "Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg",
		"intervention_name" : "Follitropin delta and HP-hMG",
		"intervention_type" : "Combination Product",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Combination Product</intervention_type>\n    <intervention_name>Follitropin delta and HP-hMG</intervention_name>\n    <description>Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg</description>\n    <arm_group_label>Follitropin delta and HP-hMG</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Shen Men acupuncture",
		"description" : "20-minute acupuncture session",
		"intervention_name" : "Shen Men acupuncture",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Shen Men acupuncture</intervention_name>\n    <description>20-minute acupuncture session</description>\n    <arm_group_label>Shen Men acupuncture</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).",
		"intervention_name" : "MRI examination",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>MRI examination</intervention_name>\n    <description>MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).</description>\n    <arm_group_label>Comatose patient</arm_group_label>\n    <arm_group_label>control volunteers</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity",
		"intervention_name" : "Blood samples",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Blood samples</intervention_name>\n    <description>Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity</description>\n    <arm_group_label>Comatose patient</arm_group_label>\n    <arm_group_label>control volunteers</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "HMPL-523 & Azacitidine",
		"description" : "Azacitidine Injection",
		"intervention_name" : "Azacitidine",
		"intervention_type" : "Drug",
		"other_name" : "Vidaza",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Azacitidine</intervention_name>\n    <description>Azacitidine Injection</description>\n    <arm_group_label>HMPL-523 &amp; Azacitidine</arm_group_label>\n    <other_name>Vidaza</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection",
		"intervention_name" : "PET examination with radiopharmaceutical drug [18F] DPA-714",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>PET examination with radiopharmaceutical drug [18F] DPA-714</intervention_name>\n    <description>Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection</description>\n    <arm_group_label>Comatose patient</arm_group_label>\n    <arm_group_label>control volunteers</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "using hyperspectral detector for evaluation excreta pattern",
		"intervention_name" : "hyperspectral imaging",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>hyperspectral imaging</intervention_name>\n    <description>using hyperspectral detector for evaluation excreta pattern</description>\n    <arm_group_label>neoplasm</arm_group_label>\n    <arm_group_label>non-neoplasm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "HMPL-523 & Azacitidine",
		"description" : "HMPL-523 tablet",
		"intervention_name" : "HMPL-523",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>HMPL-523</intervention_name>\n    <description>HMPL-523 tablet</description>\n    <arm_group_label>HMPL-523 &amp; Azacitidine</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Laminectomy",
		"description" : "A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.",
		"intervention_name" : "Laminectomy",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Laminectomy</intervention_name>\n    <description>A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.</description>\n    <arm_group_label>Laminectomy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Pharmacokinetic sample",
		"description" : "Blood and cerebrospinal fluid pharmacocinetic samples at different time point",
		"intervention_name" : "Blood and cerebrospinal fluid pharmacocinetic samples on one of the seven antibiotics prescribed in routine use",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Blood and cerebrospinal fluid pharmacocinetic samples on one of the seven antibiotics prescribed in routine use</intervention_name>\n    <description>Blood and cerebrospinal fluid pharmacocinetic samples at different time point</description>\n    <arm_group_label>Pharmacokinetic sample</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow",
		"intervention_name" : "Three dimensional power doppler",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Three dimensional power doppler</intervention_name>\n    <description>Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow</description>\n    <arm_group_label>Group without nitroglycerin</arm_group_label>\n    <arm_group_label>Group with nitroglycerin</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Small size interarcuair decompression",
		"description" : "A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.",
		"intervention_name" : "small size interarcuair decompression",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>small size interarcuair decompression</intervention_name>\n    <description>A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.</description>\n    <arm_group_label>Small size interarcuair decompression</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Standard pain education",
		"description" : "For the standard translated PNE, The English translation of \"Pain Neuroscience Education: slides for supporting and illustrating your explanation\" at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators.",
		"intervention_name" : "Standard pain education program",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Standard pain education program</intervention_name>\n    <description>For the standard translated PNE, The English translation of \"Pain Neuroscience Education: slides for supporting and illustrating your explanation\" at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators.</description>\n    <arm_group_label>Standard pain education</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group with nitroglycerin",
		"description" : "(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.",
		"intervention_name" : "Nitroglycerin",
		"intervention_type" : "Drug",
		"other_name" : "nitrodermal patch",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Nitroglycerin</intervention_name>\n    <description>(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.</description>\n    <arm_group_label>Group with nitroglycerin</arm_group_label>\n    <other_name>nitrodermal patch</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "maize maltodextrin in powder form, to be diluted in water",
		"intervention_name" : "Placebo",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>maize maltodextrin in powder form, to be diluted in water</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Culturally sensitive pain education",
		"description" : "The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.",
		"intervention_name" : "Culturally sensitive pain education",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Culturally sensitive pain education</intervention_name>\n    <description>The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.</description>\n    <arm_group_label>Culturally sensitive pain education</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.\nThis will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.\nVisit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.\nAn episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition.",
		"intervention_name" : "Two visits for evaluation",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Two visits for evaluation</intervention_name>\n    <description>Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.\nThis will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.\nVisit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.\nAn episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition.</description>\n    <arm_group_label>A group using amnesic substances</arm_group_label>\n    <arm_group_label>A control group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm 1",
		"description" : "Vaccine consists of virus-like particles of chikungunya virus antigens",
		"intervention_name" : "CHIKV VLP/unadjuvanted",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>CHIKV VLP/unadjuvanted</intervention_name>\n    <description>Vaccine consists of virus-like particles of chikungunya virus antigens</description>\n    <arm_group_label>Arm 1</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "postAlgorithm",
		"description" : "Application of blood products guided by SONOCLOT measurements",
		"intervention_name" : "Coagulation management guided by SONOCLOT",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Coagulation management guided by SONOCLOT</intervention_name>\n    <description>Application of blood products guided by SONOCLOT measurements</description>\n    <arm_group_label>postAlgorithm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "preAlgorithm",
		"description" : "Application of blood products based on clinical experience of the anesthesiologist in charge",
		"intervention_name" : "Standard coagulation management",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Standard coagulation management</intervention_name>\n    <description>Application of blood products based on clinical experience of the anesthesiologist in charge</description>\n    <arm_group_label>preAlgorithm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Diabetic patients",
		"description" : "Included patients will perform a 6 min walk test",
		"intervention_name" : "walking ability",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>walking ability</intervention_name>\n    <description>Included patients will perform a 6 min walk test</description>\n    <arm_group_label>Diabetic patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Drug - pimavanserin",
		"description" : "Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)",
		"intervention_name" : "Pimavanserin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Pimavanserin</intervention_name>\n    <description>Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)</description>\n    <arm_group_label>Drug - pimavanserin</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Anodal tDCS",
		"description" : "The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.",
		"intervention_name" : "Anodal tDCS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Anodal tDCS</intervention_name>\n    <description>The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.</description>\n    <arm_group_label>Anodal tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sham tDCS",
		"description" : "The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.",
		"intervention_name" : "Sham tDCS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Sham tDCS</intervention_name>\n    <description>The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.</description>\n    <arm_group_label>Sham tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group 1",
		"description" : "Up to 60 days of peripheral nerve stimulation",
		"intervention_name" : "Peripheral nerve stimulation",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Peripheral nerve stimulation</intervention_name>\n    <description>Up to 60 days of peripheral nerve stimulation</description>\n    <arm_group_label>Group 1</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Medications, physical therapy, or other pain treatments",
		"intervention_name" : "Standard Medical Therapy",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Standard Medical Therapy</intervention_name>\n    <description>Medications, physical therapy, or other pain treatments</description>\n    <arm_group_label>Group 1</arm_group_label>\n    <arm_group_label>Group 2</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Dexmedetomidine Hydrochloride Group",
		"description" : "Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).",
		"intervention_name" : "Dexmedetomidine Hydrochloride Group",
		"intervention_type" : "Drug",
		"other_name" : "Dexmedetomidine Hydrochloride",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dexmedetomidine Hydrochloride Group</intervention_name>\n    <description>Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).</description>\n    <arm_group_label>Dexmedetomidine Hydrochloride Group</arm_group_label>\n    <other_name>Dexmedetomidine Hydrochloride</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups",
		"intervention_name" : "TSQM-II",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>TSQM-II</intervention_name>\n    <description>Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups</description>\n    <arm_group_label>rheumatologists</arm_group_label>\n    <arm_group_label>patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Some subjects will be enrolled in a memory improvement course.",
		"intervention_name" : "Memory Improvement",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Memory Improvement</intervention_name>\n    <description>Some subjects will be enrolled in a memory improvement course.</description>\n    <arm_group_label>Immediate Intervention Group</arm_group_label>\n    <arm_group_label>Delayed Intervention Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Some subjects will be enrolled in a stress management course.",
		"intervention_name" : "Stress Management",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Stress Management</intervention_name>\n    <description>Some subjects will be enrolled in a stress management course.</description>\n    <arm_group_label>Immediate Intervention Group</arm_group_label>\n    <arm_group_label>Delayed Intervention Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Some subjects will be enrolled in a medication adherence course.",
		"intervention_name" : "Medication Adherence",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Medication Adherence</intervention_name>\n    <description>Some subjects will be enrolled in a medication adherence course.</description>\n    <arm_group_label>Immediate Intervention Group</arm_group_label>\n    <arm_group_label>Delayed Intervention Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Some subjects will be enrolled in a seizure documentation course.",
		"intervention_name" : "Seizure Documentation",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Seizure Documentation</intervention_name>\n    <description>Some subjects will be enrolled in a seizure documentation course.</description>\n    <arm_group_label>Immediate Intervention Group</arm_group_label>\n    <arm_group_label>Delayed Intervention Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "ferrous sulphate + folic acid (vitamin B9)",
		"description" : "(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.",
		"intervention_name" : "ferrous sulphate + folic acid (vitamin B9)",
		"intervention_type" : "Drug",
		"other_name" : "Ferrofol",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>ferrous sulphate + folic acid (vitamin B9)</intervention_name>\n    <description>(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.</description>\n    <arm_group_label>ferrous sulphate + folic acid (vitamin B9)</arm_group_label>\n    <other_name>Ferrofol</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment",
		"description" : "mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water",
		"intervention_name" : "Protalsafe",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Protalsafe</intervention_name>\n    <description>mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water</description>\n    <arm_group_label>Treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Film-coated oral tablets",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Film-coated oral tablets</description>\n    <arm_group_label>Placebo</arm_group_label>\n    <arm_group_label>Alcohol</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.51",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Lactoferrin",
		"description" : "(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.",
		"intervention_name" : "Lactoferrin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Lactoferrin</intervention_name>\n    <description>(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.</description>\n    <arm_group_label>Lactoferrin</arm_group_label>\n    <other_name>Pravotin</other_name>\n    <other_name>MamyVital</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Film-coated oral tablets",
		"intervention_name" : "Lemborexant",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Lemborexant</intervention_name>\n    <description>Film-coated oral tablets</description>\n    <arm_group_label>Lemborexant plus Alcohol</arm_group_label>\n    <arm_group_label>Lemborexant</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.49",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot)",
		"intervention_name" : "Alcohol",
		"intervention_type" : "Drug",
		"other_name" : "E2006",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Alcohol</intervention_name>\n    <description>0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot)</description>\n    <arm_group_label>Lemborexant plus Alcohol</arm_group_label>\n    <arm_group_label>Alcohol</arm_group_label>\n    <other_name>E2006</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.50",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "The effect of continuous quality improvements (CQI)",
		"description" : "Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.",
		"intervention_name" : "Quality Improvement",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Quality Improvement</intervention_name>\n    <description>Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.</description>\n    <arm_group_label>The effect of continuous quality improvements (CQI)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cerebrolysin and standard stroke care",
		"description" : "Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.",
		"intervention_name" : "Cerebrolysin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Cerebrolysin</intervention_name>\n    <description>Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.</description>\n    <arm_group_label>Cerebrolysin and standard stroke care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Xylometazoline + Ectoin Nasal Douche",
		"description" : "Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use",
		"intervention_name" : "Ectoin Nasal Douche",
		"intervention_type" : "Device",
		"other_name" : "END01",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Ectoin Nasal Douche</intervention_name>\n    <description>Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use</description>\n    <arm_group_label>Xylometazoline + Ectoin Nasal Douche</arm_group_label>\n    <other_name>END01</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Pembrolizumab + aRCH",
		"description" : "intravenous application, 12 months, in 3-week cycle (q3w) 200 mg",
		"intervention_name" : "Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]</intervention_name>\n    <description>intravenous application, 12 months, in 3-week cycle (q3w) 200 mg</description>\n    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "LENA with Feedback",
		"description" : "The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.",
		"intervention_name" : "Language ENhancement Assessment/intervention system",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Language ENhancement Assessment/intervention system</intervention_name>\n    <description>The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.</description>\n    <arm_group_label>LENA with Feedback</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Application of Xylometazoline Nasal Spray in accordance with the instructions for use",
		"intervention_name" : "Xylometazoline Nasal Spray",
		"intervention_type" : "Drug",
		"other_name" : "NasenSpray-ratiopharm Erwachsene (adults)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Xylometazoline Nasal Spray</intervention_name>\n    <description>Application of Xylometazoline Nasal Spray in accordance with the instructions for use</description>\n    <arm_group_label>Xylometazoline Nasal spray</arm_group_label>\n    <arm_group_label>Xylometazoline + Ectoin Nasal Douche</arm_group_label>\n    <other_name>NasenSpray-ratiopharm Erwachsene (adults)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "RAVEN WELP combination",
		"description" : "Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.",
		"intervention_name" : "RAVEN WELP combination",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>RAVEN WELP combination</intervention_name>\n    <description>Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.</description>\n    <arm_group_label>RAVEN WELP combination</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "RAVEN FIS combination",
		"description" : "Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.",
		"intervention_name" : "RAVEN FIS combination",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>RAVEN FIS combination</intervention_name>\n    <description>Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.</description>\n    <arm_group_label>RAVEN FIS combination</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "NATO WELP combination",
		"description" : "Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.",
		"intervention_name" : "NATO WELP combination",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>NATO WELP combination</intervention_name>\n    <description>Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.</description>\n    <arm_group_label>NATO WELP combination</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "NATO FIS combination",
		"description" : "Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.",
		"intervention_name" : "NATO FIS combination",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>NATO FIS combination</intervention_name>\n    <description>Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.</description>\n    <arm_group_label>NATO FIS combination</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "6 different commercially available shampoos",
		"intervention_name" : "Skin Testing of Hair cleansing products",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Skin Testing of Hair cleansing products</intervention_name>\n    <description>6 different commercially available shampoos</description>\n    <arm_group_label>Hair Cleansing product 1</arm_group_label>\n    <arm_group_label>Hair cleansing product 2</arm_group_label>\n    <arm_group_label>Hair cleansing product 3</arm_group_label>\n    <arm_group_label>Hair cleansing product 4</arm_group_label>\n    <arm_group_label>Hair cleansing product 5</arm_group_label>\n    <arm_group_label>Hair cleansing product 6</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "TissuGlu Surgical Adhesive",
		"description" : "lysine-derived urethane adhesive",
		"intervention_name" : "TissuGlu Surgical Adhesive",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>TissuGlu Surgical Adhesive</intervention_name>\n    <description>lysine-derived urethane adhesive</description>\n    <arm_group_label>TissuGlu Surgical Adhesive</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Breastfeeding and weight loss support",
		"description" : "The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.",
		"intervention_name" : "Breastfeeding and weight loss support",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Breastfeeding and weight loss support</intervention_name>\n    <description>The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.</description>\n    <arm_group_label>Breastfeeding and weight loss support</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "fMRI and EEG study",
		"description" : "fMRI and EEG study",
		"intervention_name" : "fMRI and EEG study",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>fMRI and EEG study</intervention_name>\n    <description>fMRI and EEG study</description>\n    <arm_group_label>fMRI and EEG study</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Selective Suture Ligation",
		"description" : "Suture the DVC, suspend it to the pubic bone, and then cut.",
		"intervention_name" : "Selective Suture Ligation",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Selective Suture Ligation</intervention_name>\n    <description>Suture the DVC, suspend it to the pubic bone, and then cut.</description>\n    <arm_group_label>Selective Suture Ligation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Single Suture Ligation",
		"description" : "Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.",
		"intervention_name" : "Single Suture Ligation",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Single Suture Ligation</intervention_name>\n    <description>Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.</description>\n    <arm_group_label>Single Suture Ligation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "adjuvant radiochemotherapy with cisplatin",
		"intervention_name" : "adjuvant radiochemotherapy",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>adjuvant radiochemotherapy</intervention_name>\n    <description>adjuvant radiochemotherapy with cisplatin</description>\n    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>\n    <arm_group_label>aRCH</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Staple Ligation",
		"description" : "Using a stapler that staples the DVC and then cuts it.",
		"intervention_name" : "Staple Ligation",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Staple Ligation</intervention_name>\n    <description>Using a stapler that staples the DVC and then cuts it.</description>\n    <arm_group_label>Staple Ligation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Mutual aid support group",
		"description" : "These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 10 weekly 3-hour sessions.",
		"intervention_name" : "HIV group therapy",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>HIV group therapy</intervention_name>\n    <description>These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 10 weekly 3-hour sessions.</description>\n    <arm_group_label>Mutual aid support group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.",
		"intervention_name" : "MS1819-SD",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>MS1819-SD</intervention_name>\n    <description>Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cortical Control of Grasp Patterns",
		"description" : "Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes",
		"intervention_name" : "Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system</intervention_name>\n    <description>Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes</description>\n    <arm_group_label>Cortical Control of Grasp Patterns</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cognitive remediation group therapy",
		"description" : "Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 10 weekly 3-hour sessions.",
		"intervention_name" : "CRGT",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>CRGT</intervention_name>\n    <description>Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 10 weekly 3-hour sessions.</description>\n    <arm_group_label>Cognitive remediation group therapy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.",
		"intervention_name" : "ETBX-061; adenoviral MUC1 vaccine",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>ETBX-061; adenoviral MUC1 vaccine</intervention_name>\n    <description>5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>\n    <arm_group_label>1/Dose De-Escalation</arm_group_label>\n    <arm_group_label>2/Dose expansion</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.",
		"intervention_name" : "ETBX-051; adenoviral brachyury vaccine",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>ETBX-051; adenoviral brachyury vaccine</intervention_name>\n    <description>5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>\n    <arm_group_label>1/Dose De-Escalation</arm_group_label>\n    <arm_group_label>2/Dose expansion</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Placebo matched to BBT-401-1S, oral capsule",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Placebo matched to BBT-401-1S, oral capsule</description>\n    <arm_group_label>Single Ascending Doses</arm_group_label>\n    <arm_group_label>Multiple Ascending Doses</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.",
		"intervention_name" : "ETBX-071; adenoviral PSA vaccine",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>ETBX-071; adenoviral PSA vaccine</intervention_name>\n    <description>5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>\n    <arm_group_label>1/Dose De-Escalation</arm_group_label>\n    <arm_group_label>2/Dose expansion</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "No intervention - data collection only",
		"intervention_name" : "No intervention - data collection only",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>No intervention - data collection only</intervention_name>\n    <description>No intervention - data collection only</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "App-technology group",
		"description" : "The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery",
		"intervention_name" : "App-technology to increase physical activity",
		"intervention_type" : "Behavioral",
		"other_name" : "PromMera",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>App-technology to increase physical activity</intervention_name>\n    <description>The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery</description>\n    <arm_group_label>App-technology group</arm_group_label>\n    <other_name>PromMera</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Routine calcium",
		"description" : "Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not",
		"intervention_name" : "Calcium Carbonate 1500 Mg with Vitamin D",
		"intervention_type" : "Drug",
		"other_name" : "Dicamax 1000",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Calcium Carbonate 1500 Mg with Vitamin D</intervention_name>\n    <description>Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not</description>\n    <arm_group_label>Routine calcium</arm_group_label>\n    <other_name>Dicamax 1000</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Direct Acting Antiviral Agents (DAA) arm",
		"description" : "DAA therapy in pediatric population",
		"intervention_name" : "Direct Acting Antivirals",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Direct Acting Antivirals</intervention_name>\n    <description>DAA therapy in pediatric population</description>\n    <arm_group_label>Direct Acting Antiviral Agents (DAA) arm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group BIS",
		"description" : "Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.",
		"intervention_name" : "Bispectral Index",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Bispectral Index</intervention_name>\n    <description>Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.</description>\n    <arm_group_label>Group BIS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention Group",
		"description" : "Peer-facilitated, self-care BP education delivered weekly for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $30 of groceries for 8 weeks.",
		"intervention_name" : "ENACTS",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>ENACTS</intervention_name>\n    <description>Peer-facilitated, self-care BP education delivered weekly for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $30 of groceries for 8 weeks.</description>\n    <arm_group_label>Intervention Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Workplace intervention group",
		"description" : "The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.",
		"intervention_name" : "Workplace intervention",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Workplace intervention</intervention_name>\n    <description>The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.</description>\n    <arm_group_label>Workplace intervention group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Magnetic steering",
		"description" : "The capsule was controlled to pass through the pylorus by magnet steering.",
		"intervention_name" : "magnetic steering",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>magnetic steering</intervention_name>\n    <description>The capsule was controlled to pass through the pylorus by magnet steering.</description>\n    <arm_group_label>Magnetic steering</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control",
		"description" : "Usual standard of care",
		"intervention_name" : "Control Arm",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Control Arm</intervention_name>\n    <description>Usual standard of care</description>\n    <arm_group_label>Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment Group",
		"description" : "A brace that supports the lumbar region of the spine.",
		"intervention_name" : "Lumbar back brace",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Lumbar back brace</intervention_name>\n    <description>A brace that supports the lumbar region of the spine.</description>\n    <arm_group_label>Treatment Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "LET monitoring",
		"description" : "Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.",
		"intervention_name" : "Conventional Care",
		"intervention_type" : "Procedure",
		"other_name" : "LET monitoring",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Conventional Care</intervention_name>\n    <description>Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.</description>\n    <arm_group_label>LET monitoring</arm_group_label>\n    <other_name>LET monitoring</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention",
		"description" : "The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.",
		"intervention_name" : "Intervention Arm",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Intervention Arm</intervention_name>\n    <description>The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.</description>\n    <arm_group_label>Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "A daily dose for 3 weeks -10g per day in powder form dissolved in 200ml water.",
		"intervention_name" : "Maltodextrin",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Maltodextrin</intervention_name>\n    <description>A daily dose for 3 weeks -10g per day in powder form dissolved in 200ml water.</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Esophageal thermal regulation device",
		"description" : "Use of esophageal thermal regulation device during radiofrequency ablation.",
		"intervention_name" : "EnsoETM",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>EnsoETM</intervention_name>\n    <description>Use of esophageal thermal regulation device during radiofrequency ablation.</description>\n    <arm_group_label>Esophageal thermal regulation device</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients with Crohn Disease",
		"description" : "Transabdominal ultrasound of the bowel for categorization of disease activity",
		"intervention_name" : "Diagnostic test: Ultrasound",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Diagnostic test: Ultrasound</intervention_name>\n    <description>Transabdominal ultrasound of the bowel for categorization of disease activity</description>\n    <arm_group_label>Patients with Crohn Disease</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment Prebiotic",
		"description" : "A daily dose for 3 weeks -10g per day in powder form dissolved in 200ml water.",
		"intervention_name" : "Prebiotic",
		"intervention_type" : "Dietary Supplement",
		"other_name" : "Vivinal-GOS",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Prebiotic</intervention_name>\n    <description>A daily dose for 3 weeks -10g per day in powder form dissolved in 200ml water.</description>\n    <arm_group_label>Treatment Prebiotic</arm_group_label>\n    <other_name>Vivinal-GOS</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Single Ascending Doses",
		"description" : "Single dose of BBT-401-1S, 7 dose levels, oral capsule",
		"intervention_name" : "BBT-401-1S, Single dose",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BBT-401-1S, Single dose</intervention_name>\n    <description>Single dose of BBT-401-1S, 7 dose levels, oral capsule</description>\n    <arm_group_label>Single Ascending Doses</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Multiple Ascending Doses",
		"description" : "Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule",
		"intervention_name" : "BBT-401-1S, Multiple doses",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BBT-401-1S, Multiple doses</intervention_name>\n    <description>Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule</description>\n    <arm_group_label>Multiple Ascending Doses</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group (A)",
		"description" : "group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml",
		"intervention_name" : "SST in group (A)",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>SST in group (A)</intervention_name>\n    <description>group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml</description>\n    <arm_group_label>Group (A)</arm_group_label>\n    <other_name>subscleral trabeculectomy</other_name>\n    <other_name>conventional trabeculectomy</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "group (B)",
		"description" : "group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)",
		"intervention_name" : "trabeculectomy with ESST in group (B)",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>trabeculectomy with ESST in group (B)</intervention_name>\n    <description>group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)</description>\n    <arm_group_label>group (B)</arm_group_label>\n    <other_name>modified trabeculectomy</other_name>\n    <other_name>extended subscleral tunnel</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Ampoule",
		"intervention_name" : "Midazolam",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Midazolam</intervention_name>\n    <description>Ampoule</description>\n    <arm_group_label>2- 2nd</arm_group_label>\n    <arm_group_label>3- 3rd group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention group",
		"description" : "DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.",
		"intervention_name" : "DIMINI lifestyle intervention",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>DIMINI lifestyle intervention</intervention_name>\n    <description>DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.</description>\n    <arm_group_label>Intervention group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Back school consists of patient education physical therapy exercise instruction.",
		"intervention_name" : "Back school",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Back school</intervention_name>\n    <description>Back school consists of patient education physical therapy exercise instruction.</description>\n    <arm_group_label>Control Group</arm_group_label>\n    <arm_group_label>Treatment Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Ampoule",
		"intervention_name" : "Granisetron",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Granisetron</intervention_name>\n    <description>Ampoule</description>\n    <arm_group_label>1- 1st group</arm_group_label>\n    <arm_group_label>3- 3rd group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "TAK-788 placebo-matching capsules.",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>TAK-788 placebo-matching capsules.</description>\n    <arm_group_label>Part 1 Cohort 1: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 2: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 3: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 4: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 5: TAK-788</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.47",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Education on breastfeeding pain",
		"description" : "A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.",
		"intervention_name" : "Education on breastfeeding pain",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Education on breastfeeding pain</intervention_name>\n    <description>A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.</description>\n    <arm_group_label>Education on breastfeeding pain</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "FOLFOXIRI+short-course radiation+XELOX",
		"description" : "OXALIPLATIN 130 mg/m^2 IV over 2-h, day 1 Capecitabine 1000 mg/m^2 twice daily days 1-14 every 3 weeks for 4 cycles.",
		"intervention_name" : "XELOX",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>XELOX</intervention_name>\n    <description>OXALIPLATIN 130 mg/m^2 IV over 2-h, day 1 Capecitabine 1000 mg/m^2 twice daily days 1-14 every 3 weeks for 4 cycles.</description>\n    <arm_group_label>FOLFOXIRI+short-course radiation+XELOX</arm_group_label>\n    <other_name>Capecitabine</other_name>\n    <other_name>Oxaliplatin</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "TAK-788 capsules.",
		"intervention_name" : "TAK-788",
		"intervention_type" : "Drug",
		"other_name" : "AP32788",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>TAK-788</intervention_name>\n    <description>TAK-788 capsules.</description>\n    <arm_group_label>Part 1 Cohort 1: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 2: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 3: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 4: TAK-788</arm_group_label>\n    <arm_group_label>Part 1 Cohort 5: TAK-788</arm_group_label>\n    <arm_group_label>Part 2: TAK-788 Fed + TAK-788 Fasted</arm_group_label>\n    <arm_group_label>Part 2: TAK-788 Fasted + TAK-788 Fed</arm_group_label>\n    <other_name>AP32788</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.46",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "FOLFOXIRI+short-course radiation+XELOX",
		"description" : "IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).",
		"intervention_name" : "FOLFOXIRI",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>FOLFOXIRI</intervention_name>\n    <description>IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).</description>\n    <arm_group_label>FOLFOXIRI+short-course radiation+XELOX</arm_group_label>\n    <other_name>Irinotecan</other_name>\n    <other_name>Oxaliplatin</other_name>\n    <other_name>5-Fluorouracil</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "FOLFOXIRI+short-course radiation+XELOX",
		"description" : "Patients received a short-course radiation therapy(5Gy*5) after 4 cycles of FOLFOXIRI.",
		"intervention_name" : "Short-Course Radiation Therapy(5Gy*5)",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>Short-Course Radiation Therapy(5Gy*5)</intervention_name>\n    <description>Patients received a short-course radiation therapy(5Gy*5) after 4 cycles of FOLFOXIRI.</description>\n    <arm_group_label>FOLFOXIRI+short-course radiation+XELOX</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Eyedrop administration",
		"description" : "Latanoprost ophthalmic solution administered as an eyedrop",
		"intervention_name" : "Latanoprost",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Latanoprost</intervention_name>\n    <description>Latanoprost ophthalmic solution administered as an eyedrop</description>\n    <arm_group_label>Eyedrop administration</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Me & You: Building Healthy Relationships",
		"description" : "Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).",
		"intervention_name" : "Me & You: Building Healthy Relationships",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Me &amp; You: Building Healthy Relationships</intervention_name>\n    <description>Me &amp; You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).</description>\n    <arm_group_label>Me &amp; You: Building Healthy Relationships</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.47",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Volunteers",
		"description" : "Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss",
		"intervention_name" : "Installation of 3PEGASE Sensor",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Installation of 3PEGASE Sensor</intervention_name>\n    <description>Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss</description>\n    <arm_group_label>Volunteers</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "FOLFOXIRI",
		"description" : "Irinotecan 150 mg/m^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)",
		"intervention_name" : "FOLFOXIRI",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>FOLFOXIRI</intervention_name>\n    <description>Irinotecan 150 mg/m^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)</description>\n    <arm_group_label>FOLFOXIRI</arm_group_label>\n    <other_name>Irinotecan</other_name>\n    <other_name>Oxaliplatin</other_name>\n    <other_name>5-Fluorouracil</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Pre-operative RT and TMZ",
		"description" : "Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.",
		"intervention_name" : "Temozolomide",
		"intervention_type" : "Drug",
		"other_name" : "Surgery",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Temozolomide</intervention_name>\n    <description>Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.</description>\n    <arm_group_label>Pre-operative RT and TMZ</arm_group_label>\n    <other_name>Surgery</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Pre-operative RT and TMZ",
		"description" : "Radiation is given with Temozolomide for 7 days before surgery",
		"intervention_name" : "Pre-Operative Radiation",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>Pre-Operative Radiation</intervention_name>\n    <description>Radiation is given with Temozolomide for 7 days before surgery</description>\n    <arm_group_label>Pre-operative RT and TMZ</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service",
		"intervention_name" : "osteoporotic fracture liaison service",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>osteoporotic fracture liaison service</intervention_name>\n    <description>a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.20",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Organic caffeine-free herbal tea",
		"intervention_name" : "Herbal Teas",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Herbal Teas</intervention_name>\n    <description>Organic caffeine-free herbal tea</description>\n    <arm_group_label>Herbal Tea 1</arm_group_label>\n    <arm_group_label>Herbal Tea 2</arm_group_label>\n    <arm_group_label>Herbal Tea 3</arm_group_label>\n    <arm_group_label>Herbal Tea 4</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Ultimaster stent",
		"description" : "Percutaneous coronary intervention with Ultimaster stent for long lesion",
		"intervention_name" : "Ultimaster stent",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Ultimaster stent</intervention_name>\n    <description>Percutaneous coronary intervention with Ultimaster stent for long lesion</description>\n    <arm_group_label>Ultimaster stent</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Xience alpine stent",
		"description" : "Percutaneous coronary intervention with Xience alpine stent for long lesion",
		"intervention_name" : "Xience alpine stent",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Xience alpine stent</intervention_name>\n    <description>Percutaneous coronary intervention with Xience alpine stent for long lesion</description>\n    <arm_group_label>Xience alpine stent</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) > 1000/mcL for 3 days.",
		"intervention_name" : "g-csf",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>g-csf</intervention_name>\n    <description>5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) &gt; 1000/mcL for 3 days.</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "cell dose goal: < 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight",
		"intervention_name" : "Peripheral Blood Transplant",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Peripheral Blood Transplant</intervention_name>\n    <description>cell dose goal: &lt; 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.43",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.",
		"intervention_name" : "Tacrolimus",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Tacrolimus</intervention_name>\n    <description>1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.",
		"intervention_name" : "cellcept",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>cellcept</intervention_name>\n    <description>dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "30 mg/m2 daily for 5 days",
		"intervention_name" : "Fludarabine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Fludarabine</intervention_name>\n    <description>30 mg/m2 daily for 5 days</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "200 centigray (cGy) for one day (day -1)",
		"intervention_name" : "Total Body Irradiation",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>Total Body Irradiation</intervention_name>\n    <description>200 centigray (cGy) for one day (day -1)</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Luteal Phase",
		"description" : "Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.",
		"intervention_name" : "Luteal Phase",
		"intervention_type" : "Procedure",
		"other_name" : "Second Step",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Luteal Phase</intervention_name>\n    <description>Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.</description>\n    <arm_group_label>Luteal Phase</arm_group_label>\n    <other_name>Second Step</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Johns Hopkins' conditioning regimen",
		"description" : "14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)",
		"intervention_name" : "Cyclophosphamide",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Cyclophosphamide</intervention_name>\n    <description>14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)</description>\n    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Case group: Testosterone Product",
		"description" : "Men used testosterone product following prescription",
		"intervention_name" : "Testosterone Product",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Testosterone Product</intervention_name>\n    <description>Men used testosterone product following prescription</description>\n    <arm_group_label>Case group: Testosterone Product</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Total Knee Robotically-Assisted",
		"description" : "The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.",
		"intervention_name" : "Total Knee Robotically-Assisted",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Total Knee Robotically-Assisted</intervention_name>\n    <description>The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.</description>\n    <arm_group_label>Total Knee Robotically-Assisted</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Programmed Intermittent Bolus",
		"description" : "6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus",
		"intervention_name" : "Programmed Intermittent Bolus",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Programmed Intermittent Bolus</intervention_name>\n    <description>6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus</description>\n    <arm_group_label>Programmed Intermittent Bolus</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Continuous Infusion",
		"description" : "6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion",
		"intervention_name" : "Continuous Infusion",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Continuous Infusion</intervention_name>\n    <description>6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion</description>\n    <arm_group_label>Continuous Infusion</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Probiotic 2",
		"description" : "The product under investigation is a unique probiotic.",
		"intervention_name" : "Probiotic 2",
		"intervention_type" : "Dietary Supplement",
		"other_name" : "Lactobacillus acidophilus",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Probiotic 2</intervention_name>\n    <description>The product under investigation is a unique probiotic.</description>\n    <arm_group_label>Probiotic 2</arm_group_label>\n    <other_name>Lactobacillus acidophilus</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "Microcrystalline Cellulose",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Microcrystalline Cellulose</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Internalized Control",
		"description" : "Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding",
		"intervention_name" : "Nuvagen Collagen Powder",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Nuvagen Collagen Powder</intervention_name>\n    <description>Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding</description>\n    <arm_group_label>Internalized Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Probiotic 1",
		"description" : "The product under investigation is a unique probiotic.",
		"intervention_name" : "Probiotic 1",
		"intervention_type" : "Dietary Supplement",
		"other_name" : "Bifidobacterium lactis",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Probiotic 1</intervention_name>\n    <description>The product under investigation is a unique probiotic.</description>\n    <arm_group_label>Probiotic 1</arm_group_label>\n    <other_name>Bifidobacterium lactis</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment A",
		"description" : "Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.",
		"intervention_name" : "Swisse High Strength Deep Sea Krill Oil",
		"intervention_type" : "Dietary Supplement",
		"other_name" : "Superba BOOST",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Swisse High Strength Deep Sea Krill Oil</intervention_name>\n    <description>Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.</description>\n    <arm_group_label>Treatment A</arm_group_label>\n    <other_name>Superba BOOST</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment B",
		"description" : "No therapeutic effect",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>No therapeutic effect</description>\n    <arm_group_label>Treatment B</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention Community",
		"description" : "Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.",
		"intervention_name" : "CHAP-P Sessions",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>CHAP-P Sessions</intervention_name>\n    <description>Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.</description>\n    <arm_group_label>Intervention Community</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients with injections of ESA",
		"description" : "Patients will perform ASE injections themselves or by their spouses",
		"intervention_name" : "Patients with injections of ESA",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Patients with injections of ESA</intervention_name>\n    <description>Patients will perform ASE injections themselves or by their spouses</description>\n    <arm_group_label>Patients with injections of ESA</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "cathodal tDCS",
		"description" : "The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.",
		"intervention_name" : "cathodal tDCS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>cathodal tDCS</intervention_name>\n    <description>The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.</description>\n    <arm_group_label>cathodal tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "sham tDCS",
		"description" : "The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.",
		"intervention_name" : "sham tDCS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>sham tDCS</intervention_name>\n    <description>The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.</description>\n    <arm_group_label>sham tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Experimental",
		"description" : "Expanded cord blood stem cells and engineered human endothelial cells",
		"intervention_name" : "AB-110",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>AB-110</intervention_name>\n    <description>Expanded cord blood stem cells and engineered human endothelial cells</description>\n    <arm_group_label>Experimental</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.58",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "anodal tDCS",
		"description" : "The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.",
		"intervention_name" : "anodal tDCS",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>anodal tDCS</intervention_name>\n    <description>The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.</description>\n    <arm_group_label>anodal tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Open Technique",
		"description" : "After excision of pilonidal sinus normal dressing will be applied to the area of surgery",
		"intervention_name" : "Excision of Pilonidal sinus with normal dressing",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Excision of Pilonidal sinus with normal dressing</intervention_name>\n    <description>After excision of pilonidal sinus normal dressing will be applied to the area of surgery</description>\n    <arm_group_label>Open Technique</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Follicular Phase",
		"description" : "The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.",
		"intervention_name" : "Follicular Phase",
		"intervention_type" : "Procedure",
		"other_name" : "First Step",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Follicular Phase</intervention_name>\n    <description>The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.</description>\n    <arm_group_label>Follicular Phase</arm_group_label>\n    <other_name>First Step</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers",
		"intervention_name" : "Accelerated Resolution Therapy",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Accelerated Resolution Therapy</intervention_name>\n    <description>ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers</description>\n    <arm_group_label>Intervention</arm_group_label>\n    <arm_group_label>Wait list controlled</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Non powered-NPWT",
		"description" : "After excision of pilonidal sinus Non powered-NPWT will be applied to the area",
		"intervention_name" : "NPWT for Pilonidal Surgery",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>NPWT for Pilonidal Surgery</intervention_name>\n    <description>After excision of pilonidal sinus Non powered-NPWT will be applied to the area</description>\n    <arm_group_label>Non powered-NPWT</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "placebo",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>placebo</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.",
		"intervention_name" : "transcranial magnetic stimulation of the cerebellum",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>transcranial magnetic stimulation of the cerebellum</intervention_name>\n    <description>The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.</description>\n    <arm_group_label>Sham cerebellar stimulation</arm_group_label>\n    <arm_group_label>Real cerebellar stimulation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "psychotherapy intervention group",
		"description" : "NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.",
		"intervention_name" : "psychotherapy",
		"intervention_type" : "Behavioral",
		"other_name" : "Neonatal Behavioral Observation (NBO)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>psychotherapy</intervention_name>\n    <description>NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.</description>\n    <arm_group_label>psychotherapy intervention group</arm_group_label>\n    <other_name>Neonatal Behavioral Observation (NBO)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Nicotinamide Riboside",
		"description" : "250 mg capsules (4 capsules daily)",
		"intervention_name" : "Niagen®",
		"intervention_type" : "Drug",
		"other_name" : "nicotinamide riboside chloride",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Niagen®</intervention_name>\n    <description>250 mg capsules (4 capsules daily)</description>\n    <arm_group_label>Nicotinamide Riboside</arm_group_label>\n    <other_name>nicotinamide riboside chloride</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Dexmedetomidine group",
		"description" : "0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine",
		"intervention_name" : "Dexmedetomidine group",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dexmedetomidine group</intervention_name>\n    <description>0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine</description>\n    <arm_group_label>Dexmedetomidine group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Dexamethasone group",
		"description" : "0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone",
		"intervention_name" : "Dexamethasone group",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dexamethasone group</intervention_name>\n    <description>0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone</description>\n    <arm_group_label>Dexamethasone group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Home exercise",
		"description" : "Same as above.",
		"intervention_name" : "Home exercise",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Home exercise</intervention_name>\n    <description>Same as above.</description>\n    <arm_group_label>Home exercise</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.43",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients will be given a personalized plan regarding their diet.",
		"intervention_name" : "Dietary habits plan",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Dietary habits plan</intervention_name>\n    <description>Patients will be given a personalized plan regarding their diet.</description>\n    <arm_group_label>Group A</arm_group_label>\n    <arm_group_label>Group B</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "storz videolaryngoscope",
		"intervention_name" : "storz",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>storz</intervention_name>\n    <description>storz videolaryngoscope</description>\n    <arm_group_label>heart rate</arm_group_label>\n    <arm_group_label>mean arterial pressure</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Exercise classes",
		"description" : "Same as above.",
		"intervention_name" : "Exercise class",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Exercise class</intervention_name>\n    <description>Same as above.</description>\n    <arm_group_label>Exercise classes</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.",
		"intervention_name" : "LifeWrap Compression Garment",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>LifeWrap Compression Garment</intervention_name>\n    <description>Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>\n    <arm_group_label>Full Compression</arm_group_label>\n    <arm_group_label>Abdominal and Pelvic Compression</arm_group_label>\n    <arm_group_label>Lower Limb Compression</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "airtraq videolaryngoscope",
		"intervention_name" : "airtraq",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>airtraq</intervention_name>\n    <description>airtraq videolaryngoscope</description>\n    <arm_group_label>heart rate</arm_group_label>\n    <arm_group_label>mean arterial pressure</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Caudal",
		"description" : "(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)",
		"intervention_name" : "Caudal epidural block",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Caudal epidural block</intervention_name>\n    <description>(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)</description>\n    <arm_group_label>Caudal</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Experimental",
		"description" : "Human leukocyte antigen (HLA) matched umbilical cord blood",
		"intervention_name" : "Unmanipulated Umbilical Cord Blood (UCB)",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Unmanipulated Umbilical Cord Blood (UCB)</intervention_name>\n    <description>Human leukocyte antigen (HLA) matched umbilical cord blood</description>\n    <arm_group_label>Experimental</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.57",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Culturally Adapted Decision Support Navigation Intervention",
		"description" : "Participants in this group receive culturally and linguistically adapted decision counseling from the patient navigator. Patient navigators develop an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the navigators develop individualized colorectal cancer screening plan and share the information with participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.",
		"intervention_name" : "Culturally-Adapted Decision Support Navigation Intervention",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Culturally-Adapted Decision Support Navigation Intervention</intervention_name>\n    <description>Participants in this group receive culturally and linguistically adapted decision counseling from the patient navigator. Patient navigators develop an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the navigators develop individualized colorectal cancer screening plan and share the information with participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.</description>\n    <arm_group_label>Culturally Adapted Decision Support Navigation Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "TAP",
		"description" : "(0.3 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).",
		"intervention_name" : "ultrasonography-guided TAP block",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>ultrasonography-guided TAP block</intervention_name>\n    <description>(0.3 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).</description>\n    <arm_group_label>TAP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sham",
		"description" : "SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days",
		"intervention_name" : "SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)</intervention_name>\n    <description>SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days</description>\n    <arm_group_label>Sham</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Advanced Control",
		"description" : "Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail.",
		"intervention_name" : "Advanced Control",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Advanced Control</intervention_name>\n    <description>Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail.</description>\n    <arm_group_label>Advanced Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Healthy subjects",
		"description" : "The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.",
		"intervention_name" : "Automated extracranial internal carotid artery ultrasound sensor",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Automated extracranial internal carotid artery ultrasound sensor</intervention_name>\n    <description>The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.</description>\n    <arm_group_label>Healthy subjects</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Peripheral Nerve Stimulation",
		"description" : "ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days",
		"intervention_name" : "ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)</intervention_name>\n    <description>ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days</description>\n    <arm_group_label>Peripheral Nerve Stimulation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention",
		"description" : "Professional oral care (dental hygienist), intensified oral care measures by the patient",
		"intervention_name" : "Oral care programme",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Oral care programme</intervention_name>\n    <description>Professional oral care (dental hygienist), intensified oral care measures by the patient</description>\n    <arm_group_label>Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Multifaceted Implementation Strategy",
		"description" : "Key components include:\neducational presentations to primary care providers at grand rounds\npatient information materials on ABPM and HBPM training registered nurses to assist providers with teaching patients to conduct HBPM\ninformation on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications\na computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients\nperiodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients\nan accessible, culturally-adapted and locally tailored ABPM service",
		"intervention_name" : "Multifaceted Implementation Strategy",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Multifaceted Implementation Strategy</intervention_name>\n    <description>Key components include:\neducational presentations to primary care providers at grand rounds\npatient information materials on ABPM and HBPM training registered nurses to assist providers with teaching patients to conduct HBPM\ninformation on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications\na computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients\nperiodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients\nan accessible, culturally-adapted and locally tailored ABPM service</description>\n    <arm_group_label>Multifaceted Implementation Strategy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Potassium Nitrate (KNO3)",
		"description" : "Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals [610 mg, corresponding to 6.03 mmoles of NO3-] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.",
		"intervention_name" : "Potassium Nitrate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Potassium Nitrate</intervention_name>\n    <description>Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals [610 mg, corresponding to 6.03 mmoles of NO3-] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.</description>\n    <arm_group_label>Potassium Nitrate (KNO3)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Potassium Chloride",
		"description" : "Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.",
		"intervention_name" : "Potassium Chloride",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Potassium Chloride</intervention_name>\n    <description>Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.</description>\n    <arm_group_label>Potassium Chloride</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "cooked diet with controlled amount of salt - 2 grams of salt per pacient",
		"intervention_name" : "cooked diet with controlled amount of salt",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>cooked diet with controlled amount of salt</intervention_name>\n    <description>cooked diet with controlled amount of salt - 2 grams of salt per pacient</description>\n    <arm_group_label>cooked diet with controlled amount of salt</arm_group_label>\n    <arm_group_label>cooked without salt</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Polyphenol group",
		"description" : "Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery",
		"intervention_name" : "Polyphenol group",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Polyphenol group</intervention_name>\n    <description>Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery</description>\n    <arm_group_label>Polyphenol group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Open, laparoscopic, or laparoscopically-assisted procedures\nProcedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction",
		"intervention_name" : "Major emergency gastrointestinal surgery",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Major emergency gastrointestinal surgery</intervention_name>\n    <description>Open, laparoscopic, or laparoscopically-assisted procedures\nProcedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.",
		"intervention_name" : "CT and MRI",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>CT and MRI</intervention_name>\n    <description>For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.</description>\n    <arm_group_label>Patients with greater tuberosity fractures</arm_group_label>\n    <arm_group_label>Dislocation patients with greater tuberosity fractures</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group A - fecal microbiota transplantation",
		"description" : "The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.\nAfter colon cleansing using 4 liters of Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.\nThe patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum.",
		"intervention_name" : "Fecal Microbiota Transplantation (FMT)",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>\n    <description>The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.\nAfter colon cleansing using 4 liters of Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.\nThe patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum.</description>\n    <arm_group_label>Group A - fecal microbiota transplantation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group B- Sham-transplantation",
		"description" : "The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.\nAfter colon cleansing using 4 liters of Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.\nThe patient will then sham transplantation (FMT vehicle) in the cecum.",
		"intervention_name" : "Sham-transplantation Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sham-transplantation Placebo</intervention_name>\n    <description>The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.\nAfter colon cleansing using 4 liters of Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.\nThe patient will then sham transplantation (FMT vehicle) in the cecum.</description>\n    <arm_group_label>Group B- Sham-transplantation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "albuterol sulfate and ipratropium bromide",
		"intervention_name" : "Albuterol Sulfate and Ipratropium Bromide",
		"intervention_type" : "Combination Product",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Combination Product</intervention_type>\n    <intervention_name>Albuterol Sulfate and Ipratropium Bromide</intervention_name>\n    <arm_group_label>albuterol sulfate and ipratropium bromide</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"intervention_name" : "Albuterol Sulfate",
		"intervention_type" : "Combination Product",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Combination Product</intervention_type>\n    <intervention_name>Albuterol Sulfate</intervention_name>\n    <arm_group_label>albuterol sulfate 100 mcg</arm_group_label>\n    <arm_group_label>albuterol sulfate 200 mcg</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "gaming board with single-player games",
		"description" : "upper limb training with a LED-based interactive gaming board equipped with single-player games",
		"intervention_name" : "gaming board with single-player games",
		"intervention_type" : "Other",
		"other_name" : "interactive gaming board with single-player games",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>gaming board with single-player games</intervention_name>\n    <description>upper limb training with a LED-based interactive gaming board equipped with single-player games</description>\n    <arm_group_label>gaming board with single-player games</arm_group_label>\n    <other_name>interactive gaming board with single-player games</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "gaming board with two-player games",
		"description" : "upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games",
		"intervention_name" : "gaming board with two-player games",
		"intervention_type" : "Other",
		"other_name" : "interactive gaming board with two-player competitive games",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>gaming board with two-player games</intervention_name>\n    <description>upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games</description>\n    <arm_group_label>gaming board with two-player games</arm_group_label>\n    <other_name>interactive gaming board with two-player competitive games</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Afibrinogenemia",
		"intervention_name" : "Questionnaire quality of life",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Questionnaire quality of life</intervention_name>\n    <arm_group_label>Afibrinogenemia</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "traditional wooden checkerboard",
		"description" : "upper limb training with traditional wooden checkerboard",
		"intervention_name" : "traditional wooden checkerboard",
		"intervention_type" : "Other",
		"other_name" : "checkerboard for upper limb training",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>traditional wooden checkerboard</intervention_name>\n    <description>upper limb training with traditional wooden checkerboard</description>\n    <arm_group_label>traditional wooden checkerboard</arm_group_label>\n    <other_name>checkerboard for upper limb training</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Blinatumomab",
		"description" : "Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.",
		"intervention_name" : "Blinatumomab",
		"intervention_type" : "Drug",
		"other_name" : "blincyto",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Blinatumomab</intervention_name>\n    <description>Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.</description>\n    <arm_group_label>Blinatumomab</arm_group_label>\n    <other_name>blincyto</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Mirikizumab",
		"description" : "Administered SC",
		"intervention_name" : "Mirikizumab",
		"intervention_type" : "Drug",
		"other_name" : "LY3074828",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Mirikizumab</intervention_name>\n    <description>Administered SC</description>\n    <arm_group_label>Mirikizumab</arm_group_label>\n    <other_name>LY3074828</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Morphine sulphate & Granisetron",
		"description" : "2 mL of 2 mg granisetron IV injection",
		"intervention_name" : "Granisetron",
		"intervention_type" : "Drug",
		"other_name" : "Kytril, Sancuso",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Granisetron</intervention_name>\n    <description>2 mL of 2 mg granisetron IV injection</description>\n    <arm_group_label>Morphine sulphate &amp; Granisetron</arm_group_label>\n    <other_name>Kytril, Sancuso</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Hypothermic circulatory arrest",
		"description" : "TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest",
		"intervention_name" : "Measurement of tissue oxygenation index (TOI)",
		"intervention_type" : "Diagnostic Test",
		"other_name" : "Measurement of mean blood flow velocity in the middle cerebral artery (Vmca)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Measurement of tissue oxygenation index (TOI)</intervention_name>\n    <description>TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest</description>\n    <arm_group_label>Hypothermic circulatory arrest</arm_group_label>\n    <other_name>Measurement of mean blood flow velocity in the middle cerebral artery (Vmca)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "200 ug morphine sulphate will be injected intrathecally",
		"intervention_name" : "Morphine Sulfate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Morphine Sulfate</intervention_name>\n    <description>200 ug morphine sulphate will be injected intrathecally</description>\n    <arm_group_label>Morphine sulphate &amp; Placebo</arm_group_label>\n    <arm_group_label>Morphine sulphate &amp; Granisetron</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Morphine sulphate & Placebo",
		"description" : "2 mL of normal saline 0.9% IV injection",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"other_name" : "Normal saline 0.9%",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>2 mL of normal saline 0.9% IV injection</description>\n    <arm_group_label>Morphine sulphate &amp; Placebo</arm_group_label>\n    <other_name>Normal saline 0.9%</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Orthopedic surgery patient records",
		"description" : "An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.",
		"intervention_name" : "Xarelto (rivaroxaban)",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Xarelto (rivaroxaban)</intervention_name>\n    <description>An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.</description>\n    <arm_group_label>Orthopedic surgery patient records</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Orthopedic surgery patient records",
		"description" : "An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.",
		"intervention_name" : "Lovenox (enoxaparin)",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Lovenox (enoxaparin)</intervention_name>\n    <description>An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.</description>\n    <arm_group_label>Orthopedic surgery patient records</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment",
		"description" : "25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled",
		"intervention_name" : "Gemcitabine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Gemcitabine</intervention_name>\n    <description>25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled</description>\n    <arm_group_label>Treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment",
		"description" : "25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled",
		"intervention_name" : "FOLFIRINOX",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>FOLFIRINOX</intervention_name>\n    <description>25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled</description>\n    <arm_group_label>Treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "glucose monitoring",
		"intervention_name" : "Continuing Glucose Monitor System",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Continuing Glucose Monitor System</intervention_name>\n    <description>glucose monitoring</description>\n    <arm_group_label>Blinded</arm_group_label>\n    <arm_group_label>Unblinded</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment",
		"description" : "Non-thermal ablation of tumor",
		"intervention_name" : "Irreversible Electroporation (IRE)",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Irreversible Electroporation (IRE)</intervention_name>\n    <description>Non-thermal ablation of tumor</description>\n    <arm_group_label>Treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Vitamin D pill prior to PDT",
		"description" : "10,000 units of cholecalciferol will be taken for several days prior to PDT",
		"intervention_name" : "Vitamin D",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Vitamin D</intervention_name>\n    <description>10,000 units of cholecalciferol will be taken for several days prior to PDT</description>\n    <arm_group_label>Vitamin D pill prior to PDT</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Levulan (5-aminolevulinic acid) is applied to tumors for 4 hr, then illuminated with blue light",
		"intervention_name" : "PDT",
		"intervention_type" : "Drug",
		"other_name" : "photodynamic therapy",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>PDT</intervention_name>\n    <description>Levulan (5-aminolevulinic acid) is applied to tumors for 4 hr, then illuminated with blue light</description>\n    <arm_group_label>Placebo pill prior to PDT</arm_group_label>\n    <arm_group_label>Vitamin D pill prior to PDT</arm_group_label>\n    <other_name>photodynamic therapy</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "Administered SC",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Administered SC</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo pill prior to PDT",
		"description" : "An inert placebo pill will be taken for several days prior to PDT",
		"intervention_name" : "Placebo pill",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo pill</intervention_name>\n    <description>An inert placebo pill will be taken for several days prior to PDT</description>\n    <arm_group_label>Placebo pill prior to PDT</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Mindfulness-based Intervention",
		"description" : "mindful breath, body scan, sitting meditation and walking meditation and so on.",
		"intervention_name" : "Mindfulness-based Intervention",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Mindfulness-based Intervention</intervention_name>\n    <description>mindful breath, body scan, sitting meditation and walking meditation and so on.</description>\n    <arm_group_label>Mindfulness-based Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Physical Fitness intervention",
		"description" : "giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.",
		"intervention_name" : "Physical fitness intervention",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Physical fitness intervention</intervention_name>\n    <description>giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.</description>\n    <arm_group_label>Physical Fitness intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "SOF+DAC+PEG",
		"description" : "Antiviral agent used for the treatment of hepatitis C",
		"intervention_name" : "Pegylated Interferon alfa-2a",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Pegylated Interferon alfa-2a</intervention_name>\n    <description>Antiviral agent used for the treatment of hepatitis C</description>\n    <arm_group_label>SOF+DAC+PEG</arm_group_label>\n    <other_name>Pegasys</other_name>\n    <other_name>Taspiance</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "transferrin receptor concentration",
		"description" : "Sandwich radio-imunoassay",
		"intervention_name" : "transferrin receptor concentration",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>transferrin receptor concentration</intervention_name>\n    <description>Sandwich radio-imunoassay</description>\n    <arm_group_label>transferrin receptor concentration</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Direct acting antiviral agent used for the treatment of hepatitis C",
		"intervention_name" : "Sofosbuvir",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sofosbuvir</intervention_name>\n    <description>Direct acting antiviral agent used for the treatment of hepatitis C</description>\n    <arm_group_label>SOF+DAC+PEG</arm_group_label>\n    <arm_group_label>SOF+DAC, DOT</arm_group_label>\n    <arm_group_label>SOF+DAC, standard</arm_group_label>\n    <other_name>Sovaldi</other_name>\n    <other_name>Hepcvir</other_name>\n    <other_name>MyHep</other_name>\n    <other_name>Hepcinat</other_name>\n    <other_name>Resof</other_name>\n    <other_name>SoviHep</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Direct acting antiviral agent used for the treatment of hepatitis C",
		"intervention_name" : "Daclatasvir",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Daclatasvir</intervention_name>\n    <description>Direct acting antiviral agent used for the treatment of hepatitis C</description>\n    <arm_group_label>SOF+DAC+PEG</arm_group_label>\n    <arm_group_label>SOF+DAC, DOT</arm_group_label>\n    <arm_group_label>SOF+DAC, standard</arm_group_label>\n    <other_name>Daklinza</other_name>\n    <other_name>Natdac</other_name>\n    <other_name>Daclahep</other_name>\n    <other_name>Dacihep</other_name>\n    <other_name>Hepdac</other_name>\n    <other_name>Mydekla</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Tremelimumab + Durvalumab + Radiation",
		"description" : "Radiation therapy is used to shrink cancer cells.",
		"intervention_name" : "Radiation",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>Radiation</intervention_name>\n    <description>Radiation therapy is used to shrink cancer cells.</description>\n    <arm_group_label>Tremelimumab + Durvalumab + Radiation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "cases",
		"description" : "Addiction severity index 4th version for assessment of addiction pattern.\nUPPS-P Impulsive Behavior Scale is a 59-item inventory designed to measure five distinct personality pathways to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Sensation Seeking, and Positive Urgency.\nIowa gambling task computerized version: The task involved drawing one card per trial from one of four decks (labeled as A, B, C, and D). Each deck contained 40 cards in a ﬁxed sequence which is unknown to participants at the start of the task. Next, participants are asked to select cards from the four decks to gain as much money as possible. The task ends when the 100th card is drawn, although subjects do not know this in advance.\nMRI brain examination:\nVoxel based morphometry through analysis of 3D T1 weighted sequence in order to assess total intracranial volume.\nResting state functional MRI.",
		"intervention_name" : "MRI brain",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>MRI brain</intervention_name>\n    <description>Addiction severity index 4th version for assessment of addiction pattern.\nUPPS-P Impulsive Behavior Scale is a 59-item inventory designed to measure five distinct personality pathways to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Sensation Seeking, and Positive Urgency.\nIowa gambling task computerized version: The task involved drawing one card per trial from one of four decks (labeled as A, B, C, and D). Each deck contained 40 cards in a ﬁxed sequence which is unknown to participants at the start of the task. Next, participants are asked to select cards from the four decks to gain as much money as possible. The task ends when the 100th card is drawn, although subjects do not know this in advance.\nMRI brain examination:\nVoxel based morphometry through analysis of 3D T1 weighted sequence in order to assess total intracranial volume.\nResting state functional MRI.</description>\n    <arm_group_label>cases</arm_group_label>\n    <other_name>Iowa gambling task</other_name>\n    <other_name>UPPS-P Impulsive Behavior Scale</other_name>\n    <other_name>Addiction severity index</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Doxy/TUDCA",
		"description" : "doxycicline and tauroursodeoxycholic acid",
		"intervention_name" : "Doxycycline and tauroursodeoxycholic acid",
		"intervention_type" : "Drug",
		"other_name" : "Standard of care therpay",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Doxycycline and tauroursodeoxycholic acid</intervention_name>\n    <description>doxycicline and tauroursodeoxycholic acid</description>\n    <arm_group_label>Doxy/TUDCA</arm_group_label>\n    <other_name>Standard of care therpay</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Standard of care",
		"description" : "Standard of care",
		"intervention_name" : "Standard of care",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Standard of care</intervention_name>\n    <description>Standard of care</description>\n    <arm_group_label>Standard of care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "misoprostol group",
		"description" : "( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation",
		"intervention_name" : "Misoprostol",
		"intervention_type" : "Drug",
		"other_name" : "misotac",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Misoprostol</intervention_name>\n    <description>( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation</description>\n    <arm_group_label>misoprostol group</arm_group_label>\n    <other_name>misotac</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "placebo group",
		"description" : "( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol",
		"intervention_name" : "Placebos",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebos</intervention_name>\n    <description>( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol</description>\n    <arm_group_label>placebo group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cystoprostatectomy",
		"description" : "Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection",
		"intervention_name" : "Cystoprostatectomy",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Cystoprostatectomy</intervention_name>\n    <description>Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection</description>\n    <arm_group_label>Cystoprostatectomy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Radiotherapy",
		"description" : "Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy",
		"intervention_name" : "external beam radiotherapy",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>external beam radiotherapy</intervention_name>\n    <description>Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy</description>\n    <arm_group_label>Radiotherapy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "In-line nebulization through NIV mask",
		"description" : "In-line nebulization will be given through NIV circuit.",
		"intervention_name" : "In-line nebulization through NIV mask",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>In-line nebulization through NIV mask</intervention_name>\n    <description>In-line nebulization will be given through NIV circuit.</description>\n    <arm_group_label>In-line nebulization through NIV mask</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Off-NIV nebulization",
		"description" : "Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..",
		"intervention_name" : "Off-NIV nebulization",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Off-NIV nebulization</intervention_name>\n    <description>Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..</description>\n    <arm_group_label>Off-NIV nebulization</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Coconut Oil Shake",
		"description" : "A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.",
		"intervention_name" : "Lauric acid (coconut oil)",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Lauric acid (coconut oil)</intervention_name>\n    <description>A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.</description>\n    <arm_group_label>Coconut Oil Shake</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Olive Oil Shake",
		"description" : "A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.",
		"intervention_name" : "No Lauric acid (olive oil)",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>No Lauric acid (olive oil)</intervention_name>\n    <description>A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.</description>\n    <arm_group_label>Olive Oil Shake</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Experimental group:Ginkgo biloba pills",
		"description" : "Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.",
		"intervention_name" : "Ginkgo biloba pills",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Ginkgo biloba pills</intervention_name>\n    <description>Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.</description>\n    <arm_group_label>Experimental group:Ginkgo biloba pills</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control group:placebo pills",
		"description" : "Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.",
		"intervention_name" : "placebo pills",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>placebo pills</intervention_name>\n    <description>Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.</description>\n    <arm_group_label>Control group:placebo pills</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Intravitreal injection",
		"intervention_name" : "Brolucizumab",
		"intervention_type" : "Drug",
		"other_name" : "RTH258, ESBA1008",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Brolucizumab</intervention_name>\n    <description>Intravitreal injection</description>\n    <arm_group_label>Brolucizumab 3 mg</arm_group_label>\n    <arm_group_label>Brolucizumab 6 mg</arm_group_label>\n    <other_name>RTH258, ESBA1008</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.54",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Aflibercept 2 mg",
		"description" : "Intravitreal injection",
		"intervention_name" : "Aflibercept",
		"intervention_type" : "Drug",
		"other_name" : "Eylea",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Aflibercept</intervention_name>\n    <description>Intravitreal injection</description>\n    <arm_group_label>Aflibercept 2 mg</arm_group_label>\n    <other_name>Eylea</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.55",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy",
		"intervention_name" : "Plasma dosage",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Plasma dosage</intervention_name>\n    <description>4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy</description>\n    <arm_group_label>PCOS group</arm_group_label>\n    <arm_group_label>Control group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Immediately following delivery (<12h postpartum), placental biopsies (Collection of 4 placental fragments)",
		"intervention_name" : "placental biopsy",
		"intervention_type" : "Genetic",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Genetic</intervention_type>\n    <intervention_name>placental biopsy</intervention_name>\n    <description>Immediately following delivery (&lt;12h postpartum), placental biopsies (Collection of 4 placental fragments)</description>\n    <arm_group_label>PCOS group</arm_group_label>\n    <arm_group_label>Control group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Tremelimumab + Durvalumab + Radiation",
		"description" : "Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system",
		"intervention_name" : "Tremelimumab",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Tremelimumab</intervention_name>\n    <description>Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system</description>\n    <arm_group_label>Tremelimumab + Durvalumab + Radiation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Tremelimumab + Durvalumab + Radiation",
		"description" : "Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system",
		"intervention_name" : "Durvalumab",
		"intervention_type" : "Drug",
		"other_name" : "Imfinzi",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Durvalumab</intervention_name>\n    <description>Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system</description>\n    <arm_group_label>Tremelimumab + Durvalumab + Radiation</arm_group_label>\n    <other_name>Imfinzi</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, twice per week, for 12 sessions total (in 6 weeks).",
		"intervention_name" : "Acupuncture",
		"intervention_type" : "Device",
		"other_name" : "Needling",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Acupuncture</intervention_name>\n    <description>Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, twice per week, for 12 sessions total (in 6 weeks).</description>\n    <arm_group_label>Group1a, Acupuncture on Vulvodynia</arm_group_label>\n    <arm_group_label>Group1b, Acupuncture on Vulvodynia</arm_group_label>\n    <other_name>Needling</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group2, Standard care or waiting lists",
		"description" : "PT, pain medications, nerve block, etc",
		"intervention_name" : "Standard care",
		"intervention_type" : "Other",
		"other_name" : "Routine treatments",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Standard care</intervention_name>\n    <description>PT, pain medications, nerve block, etc</description>\n    <arm_group_label>Group2, Standard care or waiting lists</arm_group_label>\n    <other_name>Routine treatments</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PTSD patients",
		"description" : "Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.",
		"intervention_name" : "Neurofeedback",
		"intervention_type" : "Behavioral",
		"other_name" : "Real time fMRI virtual reality training",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Neurofeedback</intervention_name>\n    <description>Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.</description>\n    <arm_group_label>PTSD patients</arm_group_label>\n    <other_name>Real time fMRI virtual reality training</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention",
		"intervention_name" : "Transcranial direct current stimulation (tDCS)",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Transcranial direct current stimulation (tDCS)</intervention_name>\n    <description>tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention</description>\n    <arm_group_label>Sham tDCS</arm_group_label>\n    <arm_group_label>tDCS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "38% silver diamine fluoride solution",
		"intervention_name" : "SDF",
		"intervention_type" : "Device",
		"other_name" : "Silver diamine fluoride",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>SDF</intervention_name>\n    <description>38% silver diamine fluoride solution</description>\n    <arm_group_label>SDF arm</arm_group_label>\n    <arm_group_label>Combination arm</arm_group_label>\n    <other_name>Silver diamine fluoride</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "5% sodium fluoride varnish",
		"intervention_name" : "Fluoride varnish",
		"intervention_type" : "Device",
		"other_name" : "Sodium fluoride varnish",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Fluoride varnish</intervention_name>\n    <description>5% sodium fluoride varnish</description>\n    <arm_group_label>Fluoride varnish arm</arm_group_label>\n    <arm_group_label>Combination arm</arm_group_label>\n    <other_name>Sodium fluoride varnish</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Swisse Ultiboost Memory + Focus",
		"description" : "B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.\nVitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.\nBrahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.\nVitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue.",
		"intervention_name" : "Swisse Ultiboost Memory + Focus",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Swisse Ultiboost Memory + Focus</intervention_name>\n    <description>B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.\nVitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.\nBrahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.\nVitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue.</description>\n    <arm_group_label>Swisse Ultiboost Memory + Focus</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.45",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "riboflavin (2.2mg)",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>riboflavin (2.2mg)</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.46",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "A (melflufen+bortezomib+dex)",
		"description" : "Subcutaneous administration",
		"intervention_name" : "Bortezomib",
		"intervention_type" : "Drug",
		"other_name" : "Velcade",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Bortezomib</intervention_name>\n    <description>Subcutaneous administration</description>\n    <arm_group_label>A (melflufen+bortezomib+dex)</arm_group_label>\n    <other_name>Velcade</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "B (melflufen+daratumumab+dex)",
		"description" : "Intravenous infusion",
		"intervention_name" : "Daratumumab",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Daratumumab</intervention_name>\n    <description>Intravenous infusion</description>\n    <arm_group_label>B (melflufen+daratumumab+dex)</arm_group_label>\n    <other_name>Dara</other_name>\n    <other_name>Darzalex</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Intravenous infusion",
		"intervention_name" : "Melflufen",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Melflufen</intervention_name>\n    <description>Intravenous infusion</description>\n    <arm_group_label>A (melflufen+bortezomib+dex)</arm_group_label>\n    <arm_group_label>B (melflufen+daratumumab+dex)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Oral tablets",
		"intervention_name" : "Dexamethasone",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dexamethasone</intervention_name>\n    <description>Oral tablets</description>\n    <arm_group_label>A (melflufen+bortezomib+dex)</arm_group_label>\n    <arm_group_label>B (melflufen+daratumumab+dex)</arm_group_label>\n    <other_name>Dex</other_name>\n    <other_name>Fortecortin</other_name>\n    <other_name>Decadron</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group B",
		"description" : "Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.",
		"intervention_name" : "HealthLoop mobile application",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>HealthLoop mobile application</intervention_name>\n    <description>Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.</description>\n    <arm_group_label>Group B</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Immunocompromised patients",
		"description" : "HPV vaccination",
		"intervention_name" : "nine-valent HPV vaccine",
		"intervention_type" : "Biological",
		"other_name" : "Gardasil9",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>nine-valent HPV vaccine</intervention_name>\n    <description>HPV vaccination</description>\n    <arm_group_label>Immunocompromised patients</arm_group_label>\n    <other_name>Gardasil9</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patient: Blood sampling & Feces sampling",
		"description" : "Quantitative analysis of enterohormones, citrulline and ApoB48",
		"intervention_name" : "Blood sampling",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Blood sampling</intervention_name>\n    <description>Quantitative analysis of enterohormones, citrulline and ApoB48</description>\n    <arm_group_label>Patient: Blood sampling &amp; Feces sampling</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patient: Blood sampling & Feces sampling",
		"description" : "Intestinal absorption assessment",
		"intervention_name" : "Feces sampling",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Feces sampling</intervention_name>\n    <description>Intestinal absorption assessment</description>\n    <arm_group_label>Patient: Blood sampling &amp; Feces sampling</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "MNA alone",
		"description" : "MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.",
		"intervention_name" : "MNA alone",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>MNA alone</intervention_name>\n    <description>MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.</description>\n    <arm_group_label>MNA alone</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PERCEVAL S valve",
		"description" : "The PERCEVAL S heart valve (PERCEVAL S valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.",
		"intervention_name" : "prosthetic aortic valve (PERCEVAL S valve)",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>prosthetic aortic valve (PERCEVAL S valve)</intervention_name>\n    <description>The PERCEVAL S heart valve (PERCEVAL S valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.</description>\n    <arm_group_label>PERCEVAL S valve</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients with type 1 diabetes",
		"description" : "The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.",
		"intervention_name" : "Big Five Inventory - BFI; John in Srivastava, 1999",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Big Five Inventory - BFI; John in Srivastava, 1999</intervention_name>\n    <description>The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.</description>\n    <arm_group_label>Patients with type 1 diabetes</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Modern Neuroscience Approach (MNA) plus CBT-I",
		"description" : "MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.",
		"intervention_name" : "MNA plus CBT-I",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>MNA plus CBT-I</intervention_name>\n    <description>MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.</description>\n    <arm_group_label>Modern Neuroscience Approach (MNA) plus CBT-I</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.",
		"intervention_name" : "The World Health Organization Quality of Life (WHOQOL) -BREF",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>The World Health Organization Quality of Life (WHOQOL) -BREF</intervention_name>\n    <description>The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.</description>\n    <arm_group_label>Patients with type 1 diabetes</arm_group_label>\n    <arm_group_label>Individuals without chronic diseases</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.",
		"intervention_name" : "The Satisfaction With Life Scale - SWLS",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>The Satisfaction With Life Scale - SWLS</intervention_name>\n    <description>The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.</description>\n    <arm_group_label>Patients with type 1 diabetes</arm_group_label>\n    <arm_group_label>Individuals without chronic diseases</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "30 recurrent or metastatic head and neck cancer patients",
		"description" : "Patients will be imaged on a 1.5 T or 3 T MR scanner twice within one week prior to start of treatment.",
		"intervention_name" : "MRI examinations",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>MRI examinations</intervention_name>\n    <description>Patients will be imaged on a 1.5 T or 3 T MR scanner twice within one week prior to start of treatment.</description>\n    <arm_group_label>30 recurrent or metastatic head and neck cancer patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "50 recurrent or metastatic SCC head and neck cancer patients",
		"description" : "Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).",
		"intervention_name" : "MRI examinations",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>MRI examinations</intervention_name>\n    <description>Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).</description>\n    <arm_group_label>50 recurrent or metastatic SCC head and neck cancer patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Digital cognitive aid during the management of simulated combat wounded.",
		"intervention_name" : "SIMMAXMARCHERYAN",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>SIMMAXMARCHERYAN</intervention_name>\n    <description>Digital cognitive aid during the management of simulated combat wounded.</description>\n    <arm_group_label>Digital cognitive aid</arm_group_label>\n    <arm_group_label>no digital cognitive aid</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Crowdsourced intervention",
		"description" : "Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.",
		"intervention_name" : "Crowdsourced materials",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Crowdsourced materials</intervention_name>\n    <description>Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.</description>\n    <arm_group_label>Crowdsourced intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose",
		"intervention_name" : "PNEUMOVAX™23",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>PNEUMOVAX™23</intervention_name>\n    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>\n    <arm_group_label>V114</arm_group_label>\n    <arm_group_label>Prevnar 13™</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.46",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.",
		"intervention_name" : "Vinorelbine Tartrate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Vinorelbine Tartrate</intervention_name>\n    <description>Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.</description>\n    <arm_group_label>Cohort A; KRASmt, BRAFwt, BRAF-like CC</arm_group_label>\n    <arm_group_label>Cohort B; KRASwt, BRAFmt, BRAF-like CC</arm_group_label>\n    <other_name>Navelbine</other_name>\n    <other_name>Vinorelbine</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "V114",
		"description" : "15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose",
		"intervention_name" : "V114",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>V114</intervention_name>\n    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>\n    <arm_group_label>V114</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.44",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Prevnar 13™",
		"description" : "13-valent pneumococcal conjugate vaccine with serotypes1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 ml dose",
		"intervention_name" : "Prevnar 13™",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Prevnar 13™</intervention_name>\n    <description>13-valent pneumococcal conjugate vaccine with serotypes1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 ml dose</description>\n    <arm_group_label>Prevnar 13™</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.45",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "20 mg Parecoxib + 0.75% Ropivacaine",
		"description" : "1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)",
		"intervention_name" : "Parecoxib 20 MG/ML",
		"intervention_type" : "Drug",
		"other_name" : "Dynastat® (Pfizer)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Parecoxib 20 MG/ML</intervention_name>\n    <description>1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)</description>\n    <arm_group_label>20 mg Parecoxib + 0.75% Ropivacaine</arm_group_label>\n    <other_name>Dynastat® (Pfizer)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline",
		"intervention_name" : "Ropivacaine",
		"intervention_type" : "Drug",
		"other_name" : "Naropin® (Astra Zeneca)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Ropivacaine</intervention_name>\n    <description>19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline</description>\n    <arm_group_label>20 mg Parecoxib + 0.75% Ropivacaine</arm_group_label>\n    <arm_group_label>0.75% Ropivacaine only</arm_group_label>\n    <other_name>Naropin® (Astra Zeneca)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "wearing the eye patch from 22:00 to 6:00 of the next day",
		"intervention_name" : "eye patch",
		"intervention_type" : "Device",
		"other_name" : "blinders",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>eye patch</intervention_name>\n    <description>wearing the eye patch from 22:00 to 6:00 of the next day</description>\n    <arm_group_label>eye patch</arm_group_label>\n    <arm_group_label>eye patch + DEX</arm_group_label>\n    <other_name>blinders</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Endothelium-dependent dilatation",
		"intervention_name" : "serotonin",
		"intervention_type" : "Diagnostic Test",
		"other_name" : "nitroprusside",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>serotonin</intervention_name>\n    <description>Endothelium-dependent dilatation</description>\n    <other_name>nitroprusside</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "One tablet PO daily",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>One tablet PO daily</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day",
		"intervention_name" : "Dexmedetomidine",
		"intervention_type" : "Drug",
		"other_name" : "Precedex",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dexmedetomidine</intervention_name>\n    <description>given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day</description>\n    <arm_group_label>Dexmedetomidine</arm_group_label>\n    <arm_group_label>eye patch + DEX</arm_group_label>\n    <other_name>Precedex</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Standard of Care",
		"description" : "Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.",
		"intervention_name" : "Standard of Care",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Standard of Care</intervention_name>\n    <description>Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.</description>\n    <arm_group_label>Standard of Care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Acetylsalicylic Acid (ASA)",
		"description" : "81 mg PO daily or 325 mg PO daily",
		"intervention_name" : "Acetylsalicylic acid",
		"intervention_type" : "Drug",
		"other_name" : "ASA",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Acetylsalicylic acid</intervention_name>\n    <description>81 mg PO daily or 325 mg PO daily</description>\n    <arm_group_label>Acetylsalicylic Acid (ASA)</arm_group_label>\n    <other_name>ASA</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control",
		"description" : "Participants will not view any images or videos promoting HBV and HCV testing.",
		"intervention_name" : "Control",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Control</intervention_name>\n    <description>Participants will not view any images or videos promoting HBV and HCV testing.</description>\n    <arm_group_label>Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Prehabilitation",
		"description" : "Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care",
		"intervention_name" : "Rehabilitation",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Rehabilitation</intervention_name>\n    <description>Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care</description>\n    <arm_group_label>Prehabilitation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Early corticosteroids",
		"description" : "1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11",
		"intervention_name" : "Prednisolone Sodium Phosphate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Prednisolone Sodium Phosphate</intervention_name>\n    <description>1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11</description>\n    <arm_group_label>Early corticosteroids</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11",
		"intervention_name" : "Hydroxypropyl Methylcellulose",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Hydroxypropyl Methylcellulose</intervention_name>\n    <description>1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit",
		"intervention_name" : "Chlorhexidine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Chlorhexidine</intervention_name>\n    <description>1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit</description>\n    <arm_group_label>Chlorhexidine monotherapy</arm_group_label>\n    <arm_group_label>Chlorhexidine plus povidone iodine</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Chlorhexidine plus povidone iodine",
		"description" : "1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit",
		"intervention_name" : "Povidone-Iodine",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Povidone-Iodine</intervention_name>\n    <description>1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit</description>\n    <arm_group_label>Chlorhexidine plus povidone iodine</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "For patients with ovarian, fallopian tube, or primary peritoneal cysts\nOptional\nEnrollment, 3 months after enrollment, and 6 months after enrollment",
		"intervention_name" : "Blood draw",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Blood draw</intervention_name>\n    <description>For patients with ovarian, fallopian tube, or primary peritoneal cysts\nOptional\nEnrollment, 3 months after enrollment, and 6 months after enrollment</description>\n    <arm_group_label>Arm 1: Usual Care</arm_group_label>\n    <arm_group_label>Arm 2: Integrated Care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "For patients with ovarian, fallopian tube, or primary peritoneal cysts\nOptional\nAt time of standard of care surgery",
		"intervention_name" : "Fresh tissue from ovary",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Fresh tissue from ovary</intervention_name>\n    <description>For patients with ovarian, fallopian tube, or primary peritoneal cysts\nOptional\nAt time of standard of care surgery</description>\n    <arm_group_label>Arm 1: Usual Care</arm_group_label>\n    <arm_group_label>Arm 2: Integrated Care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm 2: Integrated Care",
		"description" : "Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.",
		"intervention_name" : "Integrated psychological care",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Integrated psychological care</intervention_name>\n    <description>Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.</description>\n    <arm_group_label>Arm 2: Integrated Care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "NCCN Distress Thermometer\nPROMIS Depression & Anxiety\nQuality of Life (SF-12)\nBrief COPE\nPatient awareness and satisfaction survey",
		"intervention_name" : "Surveys",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Surveys</intervention_name>\n    <description>NCCN Distress Thermometer\nPROMIS Depression &amp; Anxiety\nQuality of Life (SF-12)\nBrief COPE\nPatient awareness and satisfaction survey</description>\n    <arm_group_label>Arm 1: Usual Care</arm_group_label>\n    <arm_group_label>Arm 2: Integrated Care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Exposure Response Prevention for tics",
		"description" : "The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.",
		"intervention_name" : "Exposure Response Prevention for tics",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Exposure Response Prevention for tics</intervention_name>\n    <description>The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.</description>\n    <arm_group_label>Exposure Response Prevention for tics</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.48",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Active Control (Psychoeducation)",
		"description" : "The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.",
		"intervention_name" : "Psychoeducation for tics",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Psychoeducation for tics</intervention_name>\n    <description>The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.</description>\n    <arm_group_label>Active Control (Psychoeducation)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.49",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Community Health Worker",
		"description" : "Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.",
		"intervention_name" : "Community Health Worker",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Community Health Worker</intervention_name>\n    <description>Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.</description>\n    <arm_group_label>Community Health Worker</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.",
		"intervention_name" : "ActiGraph",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>ActiGraph</intervention_name>\n    <description>Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Lit Control pH Up without cocoa extract",
		"description" : "dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A",
		"intervention_name" : "Lit Control pH Up",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Lit Control pH Up</intervention_name>\n    <description>dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A</description>\n    <arm_group_label>Lit Control pH Up without cocoa extract</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Lit Control pH Up with dry cocoa extract",
		"description" : "(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.",
		"intervention_name" : "dry cocoa extract",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>dry cocoa extract</intervention_name>\n    <description>(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.</description>\n    <arm_group_label>Lit Control pH Up with dry cocoa extract</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Late corticosteroids",
		"description" : "1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11",
		"intervention_name" : "Prednisolone Sodium Phosphate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Prednisolone Sodium Phosphate</intervention_name>\n    <description>1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11</description>\n    <arm_group_label>Late corticosteroids</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Late corticosteroids",
		"description" : "1 drop 4 times daily for weeks 4-5",
		"intervention_name" : "Hydroxypropyl Methylcellulose",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Hydroxypropyl Methylcellulose</intervention_name>\n    <description>1 drop 4 times daily for weeks 4-5</description>\n    <arm_group_label>Late corticosteroids</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Reverse First ICARE Training",
		"description" : "Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.",
		"intervention_name" : "Reverse First ICARE Training",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Reverse First ICARE Training</intervention_name>\n    <description>Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.</description>\n    <arm_group_label>Reverse First ICARE Training</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.",
		"intervention_name" : "ctDNA methylation in and it's Correlation wth Development and prediction of HCC",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>ctDNA methylation in and it's Correlation wth Development and prediction of HCC</intervention_name>\n    <description>Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.</description>\n    <arm_group_label>chronic hepatitis B</arm_group_label>\n    <arm_group_label>HCC Cases</arm_group_label>\n    <arm_group_label>Healthy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Aflibercept 2 mg",
		"description" : "Intravitreal injection",
		"intervention_name" : "Aflibercept",
		"intervention_type" : "Drug",
		"other_name" : "Eylea",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Aflibercept</intervention_name>\n    <description>Intravitreal injection</description>\n    <arm_group_label>Aflibercept 2 mg</arm_group_label>\n    <other_name>Eylea</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.60",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Forward First ICARE Training",
		"description" : "Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.",
		"intervention_name" : "Forward First ICARE Training",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Forward First ICARE Training</intervention_name>\n    <description>Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.</description>\n    <arm_group_label>Forward First ICARE Training</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "oral solution and tablets",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>oral solution and tablets</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Brolucizumab 6 mg",
		"description" : "Intravitreal injection",
		"intervention_name" : "Brolucizumab",
		"intervention_type" : "Drug",
		"other_name" : "RTH258, ESBA1008",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Brolucizumab</intervention_name>\n    <description>Intravitreal injection</description>\n    <arm_group_label>Brolucizumab 6 mg</arm_group_label>\n    <other_name>RTH258, ESBA1008</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.59",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention",
		"description" : "Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.",
		"intervention_name" : "Healthy Heart Score",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Healthy Heart Score</intervention_name>\n    <description>Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.</description>\n    <arm_group_label>Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "BI 730460",
		"description" : "oral solution and tablets",
		"intervention_name" : "BI 730460",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BI 730460</intervention_name>\n    <description>oral solution and tablets</description>\n    <arm_group_label>BI 730460</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "Each vial content will be administered via the catheter used for the self-catheterization",
		"intervention_name" : "placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>placebo</intervention_name>\n    <description>Each vial content will be administered via the catheter used for the self-catheterization</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "1",
		"description" : "For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.",
		"intervention_name" : "Omnigen",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Omnigen</intervention_name>\n    <description>For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.</description>\n    <arm_group_label>1</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Usual care",
		"description" : "Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.",
		"intervention_name" : "Usual care",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Usual care</intervention_name>\n    <description>Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.</description>\n    <arm_group_label>Usual care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Rec 0/0438",
		"description" : "Each vial content will be administered via the catheter used for the self-catheterization",
		"intervention_name" : "Rec 0/0438 1 mg or 2 mg",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Rec 0/0438 1 mg or 2 mg</intervention_name>\n    <description>Each vial content will be administered via the catheter used for the self-catheterization</description>\n    <arm_group_label>Rec 0/0438</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients may receive a mRNA-based vaccine intramuscularly at two-week intervals for four cycles.\nPatients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose",
		"intervention_name" : "NCI-4650, a mRNA-based, Personalized Cancer Vaccine",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>NCI-4650, a mRNA-based, Personalized Cancer Vaccine</intervention_name>\n    <description>Patients may receive a mRNA-based vaccine intramuscularly at two-week intervals for four cycles.\nPatients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose</description>\n    <arm_group_label>1/Phase I Arm</arm_group_label>\n    <arm_group_label>2/Phase II Arm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Telerehabilitation",
		"description" : "Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.",
		"intervention_name" : "Online Telerehabilitation Platform Access",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Online Telerehabilitation Platform Access</intervention_name>\n    <description>Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.</description>\n    <arm_group_label>Telerehabilitation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment",
		"description" : "KI1106 4 Capsules",
		"intervention_name" : "KI1106 4g, QD",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>KI1106 4g, QD</intervention_name>\n    <description>KI1106 4 Capsules</description>\n    <arm_group_label>Treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control",
		"description" : "Atorvastatin Calcium 20mg",
		"intervention_name" : "Atorvastatin Calcium 20mg, QD",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Atorvastatin Calcium 20mg, QD</intervention_name>\n    <description>Atorvastatin Calcium 20mg</description>\n    <arm_group_label>Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Peer Navigation",
		"description" : "Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.",
		"intervention_name" : "Peer Navigation",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Peer Navigation</intervention_name>\n    <description>Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.</description>\n    <arm_group_label>Peer Navigation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Oral administration",
		"intervention_name" : "RV3-BB",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>RV3-BB</intervention_name>\n    <description>Oral administration</description>\n    <arm_group_label>High dose RV3-BB neonatal schedule</arm_group_label>\n    <arm_group_label>Mid dose RV3-BB neonatal schedule</arm_group_label>\n    <arm_group_label>Low dose RV3-BB neonatal schedule</arm_group_label>\n    <arm_group_label>High dose RV3-BB infant schedule</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Functional appliance therapy",
		"description" : "All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.\nStage- I (pre-treatment),\nStage- II (after pre-functional therapy)\nStage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)",
		"intervention_name" : "Functional appliance therapy",
		"intervention_type" : "Procedure",
		"other_name" : "myofunctional therapy",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Functional appliance therapy</intervention_name>\n    <description>All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.\nStage- I (pre-treatment),\nStage- II (after pre-functional therapy)\nStage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)</description>\n    <arm_group_label>Functional appliance therapy</arm_group_label>\n    <other_name>myofunctional therapy</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The intervention consists of doing 12 weeks of exercises at home, with a weekly call from a health coach.",
		"intervention_name" : "Home Based Pulmonary Rehabilitation",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Home Based Pulmonary Rehabilitation</intervention_name>\n    <description>The intervention consists of doing 12 weeks of exercises at home, with a weekly call from a health coach.</description>\n    <arm_group_label>Intervention</arm_group_label>\n    <arm_group_label>Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose",
		"intervention_name" : "PNEUMOVAX™23",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>PNEUMOVAX™23</intervention_name>\n    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>\n    <arm_group_label>V114</arm_group_label>\n    <arm_group_label>Prevnar 13™</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.",
		"intervention_name" : "Low Field Magnetic Stimulation",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Low Field Magnetic Stimulation</intervention_name>\n    <description>Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.</description>\n    <arm_group_label>Active first</arm_group_label>\n    <arm_group_label>Sham first</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "V114",
		"description" : "15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose",
		"intervention_name" : "V114",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>V114</intervention_name>\n    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>\n    <arm_group_label>V114</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Prevnar 13™",
		"description" : "13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose",
		"intervention_name" : "Prevnar 13™",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Prevnar 13™</intervention_name>\n    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose</description>\n    <arm_group_label>Prevnar 13™</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "HP Pyruvate Injection two times during MRI with 45 minute rest period between in Fatty Liver Patients and Healthy Control Subjects",
		"intervention_name" : "Hyperpolarized [13C] Pyruvate Injection",
		"intervention_type" : "Drug",
		"other_name" : "HP Pyruvate Injection",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Hyperpolarized [13C] Pyruvate Injection</intervention_name>\n    <description>HP Pyruvate Injection two times during MRI with 45 minute rest period between in Fatty Liver Patients and Healthy Control Subjects</description>\n    <arm_group_label>Fatty Liver Patients</arm_group_label>\n    <arm_group_label>Healthy Control Subjects</arm_group_label>\n    <other_name>HP Pyruvate Injection</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Treatment arm",
		"description" : "Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.",
		"intervention_name" : "Compound 121564",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Compound 121564</intervention_name>\n    <description>Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.</description>\n    <arm_group_label>Treatment arm</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "All subjects",
		"description" : "Film-coated tablet",
		"intervention_name" : "BI 1467335",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BI 1467335</intervention_name>\n    <description>Film-coated tablet</description>\n    <arm_group_label>All subjects</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "All subjects",
		"description" : "Intravenous solution",
		"intervention_name" : "BI 1467335 (C-14) intravenous solution",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BI 1467335 (C-14) intravenous solution</intervention_name>\n    <description>Intravenous solution</description>\n    <arm_group_label>All subjects</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Probe drug cocktail / Ze 117",
		"description" : "Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.",
		"intervention_name" : "Ze 117",
		"intervention_type" : "Drug",
		"other_name" : "St. John's wort dry extract Ze 117",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Ze 117</intervention_name>\n    <description>Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.</description>\n    <arm_group_label>Probe drug cocktail / Ze 117</arm_group_label>\n    <other_name>St. John's wort dry extract Ze 117</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Probe drug cocktail / Ze 117",
		"description" : "Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.",
		"intervention_name" : "Probe drug cocktail",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Probe drug cocktail</intervention_name>\n    <description>Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.</description>\n    <arm_group_label>Probe drug cocktail / Ze 117</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Oral administration",
		"intervention_name" : "Placebo",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Oral administration</description>\n    <arm_group_label>High dose RV3-BB neonatal schedule</arm_group_label>\n    <arm_group_label>Mid dose RV3-BB neonatal schedule</arm_group_label>\n    <arm_group_label>Low dose RV3-BB neonatal schedule</arm_group_label>\n    <arm_group_label>High dose RV3-BB infant schedule</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Wound with local anesthesia",
		"description" : "Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.",
		"intervention_name" : "Bupivacaine",
		"intervention_type" : "Drug",
		"other_name" : "Marcaine",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Bupivacaine</intervention_name>\n    <description>Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.</description>\n    <arm_group_label>Wound with local anesthesia</arm_group_label>\n    <other_name>Marcaine</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cognitive Remediation Therapy",
		"description" : "The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.",
		"intervention_name" : "Cognitive Remediation Therapy",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Cognitive Remediation Therapy</intervention_name>\n    <description>The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.</description>\n    <arm_group_label>Cognitive Remediation Therapy</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints",
		"intervention_name" : "Spinal Manipulation",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Spinal Manipulation</intervention_name>\n    <description>HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints</description>\n    <arm_group_label>Healthy Participants</arm_group_label>\n    <arm_group_label>Acute Low back pain participants</arm_group_label>\n    <arm_group_label>Chronic low back pain participants</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Compounded standard parenteral nutrition",
		"description" : "Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.\nThe daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.\nRoute of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.",
		"intervention_name" : "Compounded standard parenteral nutrition",
		"intervention_type" : "Drug",
		"other_name" : "Compounded standard parenteral nutrition (control drug)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Compounded standard parenteral nutrition</intervention_name>\n    <description>Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.\nThe daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.\nRoute of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.</description>\n    <arm_group_label>Compounded standard parenteral nutrition</arm_group_label>\n    <other_name>Compounded standard parenteral nutrition (control drug)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.68",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Jugular ultrasound",
		"description" : "Performing a jugular ultrasound by 2 operators before and after transfusion",
		"intervention_name" : "Jugular ultrasound",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Jugular ultrasound</intervention_name>\n    <description>Performing a jugular ultrasound by 2 operators before and after transfusion</description>\n    <arm_group_label>Jugular ultrasound</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "N group",
		"description" : "single dose intra-articular injection",
		"intervention_name" : "Normal saline",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Normal saline</intervention_name>\n    <description>single dose intra-articular injection</description>\n    <arm_group_label>N group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Kabiven®",
		"description" : "Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.\nThe daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.\nRoute of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.",
		"intervention_name" : "Kabiven®",
		"intervention_type" : "Drug",
		"other_name" : "Kabiven® for intravenous use (investigational drug)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Kabiven®</intervention_name>\n    <description>Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.\nThe daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.\nRoute of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.</description>\n    <arm_group_label>Kabiven®</arm_group_label>\n    <other_name>Kabiven® for intravenous use (investigational drug)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.67",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "H group",
		"description" : "single dose intra-articular injection",
		"intervention_name" : "Hyruan-One",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Hyruan-One</intervention_name>\n    <description>single dose intra-articular injection</description>\n    <arm_group_label>H group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "S group",
		"description" : "single dose intra-articular injection",
		"intervention_name" : "Hylan G-F 20",
		"intervention_type" : "Drug",
		"other_name" : "Synvisc",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Hylan G-F 20</intervention_name>\n    <description>single dose intra-articular injection</description>\n    <arm_group_label>S group</arm_group_label>\n    <other_name>Synvisc</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Interventional Bupivacaine",
		"description" : "20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).",
		"intervention_name" : "Bupivacaine Group",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Bupivacaine Group</intervention_name>\n    <description>20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).</description>\n    <arm_group_label>Interventional Bupivacaine</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Interventional Placebo",
		"description" : "20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).</description>\n    <arm_group_label>Interventional Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention group",
		"description" : "OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer wirelessly connected to a weight scale. Each patient will receive one system, and the system will have some patient specific information regarding the flexible (loop-) diuretics scheme.\nThe patient will be instructed to step up on the weight scale daily, and will be exposed to some brief information on how to live better with heart failure, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in heart failure status, the patient is encouraged on-screen to contact his/her health care provider via telephone.",
		"intervention_name" : "OPTILOGG",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>OPTILOGG</intervention_name>\n    <description>OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer wirelessly connected to a weight scale. Each patient will receive one system, and the system will have some patient specific information regarding the flexible (loop-) diuretics scheme.\nThe patient will be instructed to step up on the weight scale daily, and will be exposed to some brief information on how to live better with heart failure, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in heart failure status, the patient is encouraged on-screen to contact his/her health care provider via telephone.</description>\n    <arm_group_label>Intervention group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control group",
		"description" : "Patients in the control group will be subject to standard heart failure care.",
		"intervention_name" : "Standard care",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Standard care</intervention_name>\n    <description>Patients in the control group will be subject to standard heart failure care.</description>\n    <arm_group_label>Control group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Vaginal Suppositories",
		"description" : "in a minimally sufficient therapeutic dose",
		"intervention_name" : "BIBW2992",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BIBW2992</intervention_name>\n    <description>in a minimally sufficient therapeutic dose</description>\n    <arm_group_label>Vaginal Suppositories</arm_group_label>\n    <other_name>Afatinib</other_name>\n    <other_name>Giotrif</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Vaginal Suppositories",
		"description" : "in a minimally sufficient therapeutic dose",
		"intervention_name" : "Axitinib",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Axitinib</intervention_name>\n    <description>in a minimally sufficient therapeutic dose</description>\n    <arm_group_label>Vaginal Suppositories</arm_group_label>\n    <other_name>AG013736;</other_name>\n    <other_name>Inlyta</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.",
		"intervention_name" : "Standard of care drug",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Standard of care drug</intervention_name>\n    <description>This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Vaginal Suppositories",
		"description" : "in a minimally sufficient therapeutic dose",
		"intervention_name" : "Linifanib",
		"intervention_type" : "Biological",
		"other_name" : "ABT869",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Linifanib</intervention_name>\n    <description>in a minimally sufficient therapeutic dose</description>\n    <arm_group_label>Vaginal Suppositories</arm_group_label>\n    <other_name>ABT869</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1",
		"intervention_name" : "skin biopsy before and after NB-UVB phototherapy",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>skin biopsy before and after NB-UVB phototherapy</intervention_name>\n    <description>skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1</description>\n    <arm_group_label>psoriasis patients</arm_group_label>\n    <arm_group_label>controls</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm A-Sulfatinib T capsule",
		"description" : "Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.",
		"intervention_name" : "Sulfatinib T capsule",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sulfatinib T capsule</intervention_name>\n    <description>Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.</description>\n    <arm_group_label>Arm A-Sulfatinib T capsule</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "group 3; combination group",
		"description" : "Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.",
		"intervention_name" : "Intradialytic Parenteral Nutrition; Kabiven central",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Intradialytic Parenteral Nutrition; Kabiven central</intervention_name>\n    <description>Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.</description>\n    <arm_group_label>group 3; combination group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "TissuGlu Surgical Adhesive",
		"intervention_name" : "TissuGlu Surgical Adhesive",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>TissuGlu Surgical Adhesive</intervention_name>\n    <arm_group_label>TissuGlu Surgical Adhesive</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The app consists of videos depicting each exercise and ability to track adherence to exercises.",
		"intervention_name" : "Home app intervention",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Home app intervention</intervention_name>\n    <description>The app consists of videos depicting each exercise and ability to track adherence to exercises.</description>\n    <arm_group_label>Intensive treatment</arm_group_label>\n    <arm_group_label>Home app intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. ]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.",
		"intervention_name" : "Oral Nutritional Support; Nutrena",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Oral Nutritional Support; Nutrena</intervention_name>\n    <description>Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. ]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.</description>\n    <arm_group_label>1;Oral nutritional support (ONS)</arm_group_label>\n    <arm_group_label>group 3; combination group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Ancillary studies",
		"intervention_name" : "Survey Administration",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Survey Administration</intervention_name>\n    <description>Ancillary studies</description>\n    <arm_group_label>Arm I (discontinued IST)</arm_group_label>\n    <arm_group_label>Arm II (continued IST)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intensive treatment",
		"description" : "The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.",
		"intervention_name" : "Occupational therapy",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Occupational therapy</intervention_name>\n    <description>The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.</description>\n    <arm_group_label>Intensive treatment</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Liraglutide Pen Injector (Saxenda)",
		"description" : "daily sc injection of liraglutide with final dose of 3mg daily",
		"intervention_name" : "Liraglutide Pen Injector [Saxenda]",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Liraglutide Pen Injector [Saxenda]</intervention_name>\n    <description>daily sc injection of liraglutide with final dose of 3mg daily</description>\n    <arm_group_label>Liraglutide Pen Injector (Saxenda)</arm_group_label>\n    <other_name>Liraglutide 3mg</other_name>\n    <other_name>Saxenda</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.46",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo liraglutide pen injector",
		"description" : "daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo",
		"intervention_name" : "Placebo Liraglutide Pen Injector",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo Liraglutide Pen Injector</intervention_name>\n    <description>daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>\n    <arm_group_label>Placebo liraglutide pen injector</arm_group_label>\n    <other_name>Placebo Saxenda</other_name>\n    <other_name>Placebo liraglutide 3 mg</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.47",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Solution for infusion",
		"intervention_name" : "BI 655130",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BI 655130</intervention_name>\n    <description>Solution for infusion</description>\n    <arm_group_label>Group 2- Small Dose Group</arm_group_label>\n    <arm_group_label>Group 3- Medium Dose Group</arm_group_label>\n    <arm_group_label>Group 4 - High Dose Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group 1- Placebo Group",
		"description" : "Solution for infusion",
		"intervention_name" : "Placebo",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Solution for infusion</description>\n    <arm_group_label>Group 1- Placebo Group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "trientine with chemotherapy",
		"description" : "pegylated liposomal doxorubicin 40mg/m2 IV D1",
		"intervention_name" : "pegylated liposomal doxorubicin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>pegylated liposomal doxorubicin</intervention_name>\n    <description>pegylated liposomal doxorubicin 40mg/m2 IV D1</description>\n    <arm_group_label>trientine with chemotherapy</arm_group_label>\n    <other_name>trientine dihydrochloride</other_name>\n    <other_name>carboplatin</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "trientine with chemotherapy",
		"description" : "carboplatin AUC 4 IV D1",
		"intervention_name" : "carboplatin",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>carboplatin</intervention_name>\n    <description>carboplatin AUC 4 IV D1</description>\n    <arm_group_label>trientine with chemotherapy</arm_group_label>\n    <other_name>trientine dihydrochloride</other_name>\n    <other_name>pegylated liposomal doxorubicin</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm B-Sulfatinib R capsule",
		"description" : "Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.",
		"intervention_name" : "Sulfatinib R capsule",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Sulfatinib R capsule</intervention_name>\n    <description>Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.</description>\n    <arm_group_label>Arm B-Sulfatinib R capsule</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "trientine with chemotherapy",
		"description" : "trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)",
		"intervention_name" : "trientine dihydrochloride",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>trientine dihydrochloride</intervention_name>\n    <description>trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)</description>\n    <arm_group_label>trientine with chemotherapy</arm_group_label>\n    <other_name>pegylated liposomal doxorubicin</other_name>\n    <other_name>carboplatin</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention",
		"description" : "The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.\nThe intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour.",
		"intervention_name" : "Reducing/breaking prolonged sitting",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Reducing/breaking prolonged sitting</intervention_name>\n    <description>The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.\nThe intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour.</description>\n    <arm_group_label>Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.57",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Low-dose dual-energy CT imaging",
		"intervention_name" : "GE CT 750 HD",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>GE CT 750 HD</intervention_name>\n    <description>Low-dose dual-energy CT imaging</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "High-Risk Normotensives",
		"description" : "At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. This dynamic testing will include assessment of renal blood flow measured via para-aminohippurate clearance.",
		"intervention_name" : "Para-Aminohippurate",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Para-Aminohippurate</intervention_name>\n    <description>At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. This dynamic testing will include assessment of renal blood flow measured via para-aminohippurate clearance.</description>\n    <arm_group_label>High-Risk Normotensives</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "CD19-directed CAR-T cells",
		"description" : "CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg",
		"intervention_name" : "CD19-directed CAR-T cells",
		"intervention_type" : "Biological",
		"other_name" : "Anti-CD19 chimeric antigen receptor T cells (C- CAR011)",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>CD19-directed CAR-T cells</intervention_name>\n    <description>CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg</description>\n    <arm_group_label>CD19-directed CAR-T cells</arm_group_label>\n    <other_name>Anti-CD19 chimeric antigen receptor T cells (C- CAR011)</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "High-Risk Normotensives",
		"description" : "At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium restricted diet. The diet will consist of <40 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.",
		"intervention_name" : "Restricted sodium diet",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Restricted sodium diet</intervention_name>\n    <description>At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium restricted diet. The diet will consist of &lt;40 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.</description>\n    <arm_group_label>High-Risk Normotensives</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "High-Risk Normotensives",
		"description" : "At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The dynamic testing will include a one hour infusion of angiotensin II (3 ng/kg/min) which will permit assessments of angiotensin II stimulated blood pressure, renal blood flow, and adrenal aldosterone secretion.",
		"intervention_name" : "Angiotensin II",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Angiotensin II</intervention_name>\n    <description>At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The dynamic testing will include a one hour infusion of angiotensin II (3 ng/kg/min) which will permit assessments of angiotensin II stimulated blood pressure, renal blood flow, and adrenal aldosterone secretion.</description>\n    <arm_group_label>High-Risk Normotensives</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Head-to-head comparison between:\nCADScor and Diamond-Foster score\nRb PET and 3T CMRI\nQFR and ICA-FFR",
		"intervention_name" : "Diagnostic tests",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Diagnostic tests</intervention_name>\n    <description>Head-to-head comparison between:\nCADScor and Diamond-Foster score\nRb PET and 3T CMRI\nQFR and ICA-FFR</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "High-Risk Normotensives",
		"description" : "At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The diet will consist of >180 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.",
		"intervention_name" : "Sodium loaded diet",
		"intervention_type" : "Dietary Supplement",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Dietary Supplement</intervention_type>\n    <intervention_name>Sodium loaded diet</intervention_name>\n    <description>At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The diet will consist of &gt;180 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.</description>\n    <arm_group_label>High-Risk Normotensives</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm I (discontinued IST)",
		"description" : "Discontinued IST",
		"intervention_name" : "Immunosuppressive Therapy",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Immunosuppressive Therapy</intervention_name>\n    <description>Discontinued IST</description>\n    <arm_group_label>Arm I (discontinued IST)</arm_group_label>\n    <other_name>Anti-Rejection Therapy</other_name>\n    <other_name>immunosuppression</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Arm II (continued IST)",
		"description" : "Continued IST",
		"intervention_name" : "Immunosuppressive Therapy",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Immunosuppressive Therapy</intervention_name>\n    <description>Continued IST</description>\n    <arm_group_label>Arm II (continued IST)</arm_group_label>\n    <other_name>Anti-Rejection Therapy</other_name>\n    <other_name>immunosuppression</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "CESM VS MRI",
		"description" : "Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone",
		"intervention_name" : "CESM",
		"intervention_type" : "Device",
		"other_name" : "Contrast Enhanced Spectral Mammography",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>CESM</intervention_name>\n    <description>Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone</description>\n    <arm_group_label>CESM VS MRI</arm_group_label>\n    <other_name>Contrast Enhanced Spectral Mammography</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "CESM VS MRI",
		"description" : "MRI uses magnets to create a detailed image of the tissues and bones inside of the body",
		"intervention_name" : "MRI",
		"intervention_type" : "Device",
		"other_name" : "Magnetic Resonance Imaging",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>MRI</intervention_name>\n    <description>MRI uses magnets to create a detailed image of the tissues and bones inside of the body</description>\n    <arm_group_label>CESM VS MRI</arm_group_label>\n    <other_name>Magnetic Resonance Imaging</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "European Union (EU) Avastin®",
		"description" : "EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.",
		"intervention_name" : "EU-Avastin®",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>EU-Avastin®</intervention_name>\n    <description>EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.</description>\n    <arm_group_label>European Union (EU) Avastin®</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.38",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "China (CN) Avastin®",
		"description" : "CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.",
		"intervention_name" : "CN-Avastin®",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>CN-Avastin®</intervention_name>\n    <description>CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.</description>\n    <arm_group_label>China (CN) Avastin®</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.39",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "HLX04",
		"description" : "HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.",
		"intervention_name" : "HLX04",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>HLX04</intervention_name>\n    <description>HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.</description>\n    <arm_group_label>HLX04</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "United States (US) Avastin®",
		"description" : "US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.",
		"intervention_name" : "US-Avastin®",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>US-Avastin®</intervention_name>\n    <description>US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.</description>\n    <arm_group_label>United States (US) Avastin®</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Incremental theory of personality",
		"description" : "The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by \"thoughts and feelings in brains,\" and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance.",
		"intervention_name" : "Incremental theory of personality",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Incremental theory of personality</intervention_name>\n    <description>The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by \"thoughts and feelings in brains,\" and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance.</description>\n    <arm_group_label>Incremental theory of personality</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Educational intervention",
		"description" : "The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.",
		"intervention_name" : "Educational Intervention",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Educational Intervention</intervention_name>\n    <description>The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.</description>\n    <arm_group_label>Educational intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.43",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo Platform",
		"description" : "The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.",
		"intervention_name" : "Placebo Platform",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Placebo Platform</intervention_name>\n    <description>The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.</description>\n    <arm_group_label>Placebo Platform</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.",
		"intervention_name" : "Lower-body-low-pressure chamber",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Lower-body-low-pressure chamber</intervention_name>\n    <description>The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.</description>\n    <arm_group_label>Progressive bleeding simulation</arm_group_label>\n    <arm_group_label>Prolonged bleeding simulation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PET-based, dose-painted, accelerated chemoradiotherapy,",
		"description" : "Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.",
		"intervention_name" : "PET-based, dose-painted, accelerated chemoradiotherapy",
		"intervention_type" : "Combination Product",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Combination Product</intervention_type>\n    <intervention_name>PET-based, dose-painted, accelerated chemoradiotherapy</intervention_name>\n    <description>Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.</description>\n    <arm_group_label>PET-based, dose-painted, accelerated chemoradiotherapy,</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Vibration Platform",
		"description" : "The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.",
		"intervention_name" : "Vibration Platform",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Vibration Platform</intervention_name>\n    <description>The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.</description>\n    <arm_group_label>Vibration Platform</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold",
		"intervention_name" : "Interferential current",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Interferential current</intervention_name>\n    <description>interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold</description>\n    <arm_group_label>Healthy group</arm_group_label>\n    <arm_group_label>LBP group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intervention",
		"description" : "The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.",
		"intervention_name" : "COPE for Asthma",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>COPE for Asthma</intervention_name>\n    <description>The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.</description>\n    <arm_group_label>Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "TLA device",
		"description" : "Record of the time to first asthma exacerbation, lung function and exhaled NO level",
		"intervention_name" : "Nocturnal Temperature Controlled Laminar Flow Device",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Nocturnal Temperature Controlled Laminar Flow Device</intervention_name>\n    <description>Record of the time to first asthma exacerbation, lung function and exhaled NO level</description>\n    <arm_group_label>TLA device</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "None device",
		"description" : "Record of the time to first asthma exacerbation, lung function and exhaled NO level",
		"intervention_name" : "None Device",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>None Device</intervention_name>\n    <description>Record of the time to first asthma exacerbation, lung function and exhaled NO level</description>\n    <arm_group_label>None device</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "ACT-ETP",
		"description" : "To increase patients' participation by improving their level of coping with chronic pain.",
		"intervention_name" : "Acceptance & Commitment Therapy-Exposure and Perspective Taking",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Acceptance &amp; Commitment Therapy-Exposure and Perspective Taking</intervention_name>\n    <description>To increase patients' participation by improving their level of coping with chronic pain.</description>\n    <arm_group_label>ACT-ETP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.",
		"intervention_name" : "anterior segment Ocular Coherence Tomography",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>anterior segment Ocular Coherence Tomography</intervention_name>\n    <description>anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.</description>\n    <arm_group_label>femtosecond_laser</arm_group_label>\n    <arm_group_label>moria_microkeratome</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.\nThe questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password.",
		"intervention_name" : "Questionnaires",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Questionnaires</intervention_name>\n    <description>Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.\nThe questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password.</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "elevated sperm DNA fragmentation",
		"description" : "The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI",
		"intervention_name" : "ICSI",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>ICSI</intervention_name>\n    <description>The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI</description>\n    <arm_group_label>elevated sperm DNA fragmentation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Venetoclax + Dinaciclib",
		"description" : "tablet, oral",
		"intervention_name" : "Venetoclax",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Venetoclax</intervention_name>\n    <description>tablet, oral</description>\n    <arm_group_label>Venetoclax + Dinaciclib</arm_group_label>\n    <other_name>ABT-199</other_name>\n    <other_name>GDC-0199</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Venetoclax + Dinaciclib",
		"description" : "intravenous",
		"intervention_name" : "Dinaciclib",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dinaciclib</intervention_name>\n    <description>intravenous</description>\n    <arm_group_label>Venetoclax + Dinaciclib</arm_group_label>\n    <other_name>MK-7965</other_name>\n    <other_name>SCH-727965</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Administered SC.",
		"intervention_name" : "LY3298176",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>LY3298176</intervention_name>\n    <description>Administered SC.</description>\n    <arm_group_label>LY3298176 - Healthy</arm_group_label>\n    <arm_group_label>LY3298176 - Mild Renal Impairment</arm_group_label>\n    <arm_group_label>LY3298176 - Moderate Renal Impairment</arm_group_label>\n    <arm_group_label>LY3298176 - Severe Renal Impairment</arm_group_label>\n    <arm_group_label>LY3298176 - End Stage Renal Disease (ESRD)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group Infraclavicular",
		"description" : "Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)",
		"intervention_name" : "Infraclavicular brachial plexus block",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Infraclavicular brachial plexus block</intervention_name>\n    <description>Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)</description>\n    <arm_group_label>Group Infraclavicular</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Rigid and Elastic registration softwares",
		"description" : "Fusion assisting software for image-guided intervention",
		"intervention_name" : "Biomechanical computer program",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Biomechanical computer program</intervention_name>\n    <description>Fusion assisting software for image-guided intervention</description>\n    <arm_group_label>Rigid and Elastic registration softwares</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial",
		"intervention_name" : "comparaison between DE and DTF in prediction of extubation success",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>comparaison between DE and DTF in prediction of extubation success</intervention_name>\n    <description>diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.21",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Multicomponent Intervention",
		"description" : "The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.",
		"intervention_name" : "Multicomponent Intervention",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Multicomponent Intervention</intervention_name>\n    <description>The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.</description>\n    <arm_group_label>Multicomponent Intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Enhanced Usual Care",
		"description" : "We will provide an up-to-date clinical guideline for hypertension management to providers. We will conduct a webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial. Otherwise, we will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients",
		"intervention_name" : "Enhanced Usual Care",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Enhanced Usual Care</intervention_name>\n    <description>We will provide an up-to-date clinical guideline for hypertension management to providers. We will conduct a webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial. Otherwise, we will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients</description>\n    <arm_group_label>Enhanced Usual Care</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patient visiting pediatricians",
		"description" : "mucolytics, antitussives or antibiotics for upper respiratory infections (infants)",
		"intervention_name" : "Mucolytic",
		"intervention_type" : "Drug",
		"other_name" : "Mucolytics",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Mucolytic</intervention_name>\n    <description>mucolytics, antitussives or antibiotics for upper respiratory infections (infants)</description>\n    <arm_group_label>Patient visiting pediatricians</arm_group_label>\n    <other_name>Mucolytics</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patient visiting pediatricians",
		"description" : "treatment with ibuprofen and paracetamol (infants)",
		"intervention_name" : "Ibuprofen and paracetamol",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Ibuprofen and paracetamol</intervention_name>\n    <description>treatment with ibuprofen and paracetamol (infants)</description>\n    <arm_group_label>Patient visiting pediatricians</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Chronic Myeloid Leukemia",
		"description" : "Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment",
		"intervention_name" : "Collection of blood and bone marrow",
		"intervention_type" : "Biological",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Biological</intervention_type>\n    <intervention_name>Collection of blood and bone marrow</intervention_name>\n    <description>Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment</description>\n    <arm_group_label>Chronic Myeloid Leukemia</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "All patients",
		"description" : "3 extra scans with FDG-PET/CT and 4 blood samples",
		"intervention_name" : "PET/CT",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>PET/CT</intervention_name>\n    <description>3 extra scans with FDG-PET/CT and 4 blood samples</description>\n    <arm_group_label>All patients</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Placebo capsule",
		"intervention_name" : "Avicel PH101 (Microcrystalline Cellulose NF) for Compounding",
		"intervention_type" : "Drug",
		"other_name" : "Avicel",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Avicel PH101 (Microcrystalline Cellulose NF) for Compounding</intervention_name>\n    <description>Placebo capsule</description>\n    <arm_group_label>Placebo and narcotic</arm_group_label>\n    <arm_group_label>Placebo without narcotic</arm_group_label>\n    <other_name>Avicel</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.",
		"intervention_name" : "Oxycodone",
		"intervention_type" : "Drug",
		"other_name" : "Tylox, Percodan, OxyContin",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Oxycodone</intervention_name>\n    <description>Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.</description>\n    <arm_group_label>Dextromethorphan and narcotic</arm_group_label>\n    <arm_group_label>Placebo and narcotic</arm_group_label>\n    <other_name>Tylox, Percodan, OxyContin</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients undergoing Mohs surgery",
		"description" : "Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.",
		"intervention_name" : "Fast Raman",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Fast Raman</intervention_name>\n    <description>Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.</description>\n    <arm_group_label>Patients undergoing Mohs surgery</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Dextromethorphan capsule",
		"intervention_name" : "Dextromethorphan Hydrobromide",
		"intervention_type" : "Drug",
		"other_name" : "Robitussin, Delsym",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Dextromethorphan Hydrobromide</intervention_name>\n    <description>Dextromethorphan capsule</description>\n    <arm_group_label>Dextromethorphan and narcotic</arm_group_label>\n    <arm_group_label>Dextromethorphan without narcotic</arm_group_label>\n    <other_name>Robitussin, Delsym</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Group Axillary",
		"description" : "Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)",
		"intervention_name" : "axillary brachial plexus block",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>axillary brachial plexus block</intervention_name>\n    <description>Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)</description>\n    <arm_group_label>Group Axillary</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "intubation using lightwand",
		"intervention_name" : "lightwand intubation",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>lightwand intubation</intervention_name>\n    <description>intubation using lightwand</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Shaping CM",
		"description" : "Behavioral reinforcement for alcohol abstinence",
		"intervention_name" : "Shaping CM",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Shaping CM</intervention_name>\n    <description>Behavioral reinforcement for alcohol abstinence</description>\n    <arm_group_label>Shaping CM</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.43",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Intubated patient",
		"description" : "Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.",
		"intervention_name" : "Tugging Endotracheal Tube",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Tugging Endotracheal Tube</intervention_name>\n    <description>Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.</description>\n    <arm_group_label>Intubated patient</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Usual CM",
		"description" : "Behavioral reinforcement for alcohol abstinence",
		"intervention_name" : "Usual CM",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Usual CM</intervention_name>\n    <description>Behavioral reinforcement for alcohol abstinence</description>\n    <arm_group_label>Usual CM</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "High-Magnitude CM",
		"description" : "Behavioral reinforcement for alcohol abstinence",
		"intervention_name" : "High-Magnitude CM",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>High-Magnitude CM</intervention_name>\n    <description>Behavioral reinforcement for alcohol abstinence</description>\n    <arm_group_label>High-Magnitude CM</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PEGPH20 + Avelumab",
		"description" : "PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.",
		"intervention_name" : "PEGylated Recombinant Human Hyaluronidase (PEGPH20)",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>PEGylated Recombinant Human Hyaluronidase (PEGPH20)</intervention_name>\n    <description>PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.</description>\n    <arm_group_label>PEGPH20 + Avelumab</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PEGPH20 + Avelumab",
		"description" : "Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.",
		"intervention_name" : "Avelumab",
		"intervention_type" : "Drug",
		"other_name" : "MSB0010718C",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Avelumab</intervention_name>\n    <description>Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.</description>\n    <arm_group_label>PEGPH20 + Avelumab</arm_group_label>\n    <other_name>MSB0010718C</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cognitive Behavior Therapy with NRT",
		"description" : "Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.",
		"intervention_name" : "Nicotine Replacement Therapy",
		"intervention_type" : "Drug",
		"other_name" : "Nicotine Patch",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Nicotine Replacement Therapy</intervention_name>\n    <description>Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.</description>\n    <arm_group_label>Cognitive Behavior Therapy with NRT</arm_group_label>\n    <other_name>Nicotine Patch</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Participants will be referred to local AHEC/Quitline for treatment",
		"intervention_name" : "Referral to AHEC/Quitline",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Referral to AHEC/Quitline</intervention_name>\n    <description>Participants will be referred to local AHEC/Quitline for treatment</description>\n    <arm_group_label>Referral to Area Health Education Center</arm_group_label>\n    <arm_group_label>Referral to Qutiline</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "image tests in non-specific lumbago",
		"intervention_name" : "Lumbago",
		"intervention_type" : "Radiation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Radiation</intervention_type>\n    <intervention_name>Lumbago</intervention_name>\n    <description>image tests in non-specific lumbago</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.33",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patient visiting pediatricians",
		"description" : "antibiotics for pharyngitis (infants)",
		"intervention_name" : "Antimicrobial agent",
		"intervention_type" : "Drug",
		"other_name" : "Antibiotics",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Antimicrobial agent</intervention_name>\n    <description>antibiotics for pharyngitis (infants)</description>\n    <arm_group_label>Patient visiting pediatricians</arm_group_label>\n    <other_name>Antibiotics</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events",
		"intervention_name" : "Lipid-lowering drug",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Lipid-lowering drug</intervention_name>\n    <description>Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "Screening for prostate cancer in asymptomatic patients",
		"intervention_name" : "Prostate cancer",
		"intervention_type" : "Diagnostic Test",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Diagnostic Test</intervention_type>\n    <intervention_name>Prostate cancer</intervention_name>\n    <description>Screening for prostate cancer in asymptomatic patients</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "paracetamol 1g for more than 3 days",
		"intervention_name" : "paracetamol",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>paracetamol</intervention_name>\n    <description>paracetamol 1g for more than 3 days</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy",
		"intervention_name" : "Antimicrobial agent",
		"intervention_type" : "Drug",
		"other_name" : "Antibiotics",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Antimicrobial agent</intervention_name>\n    <description>antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n    <other_name>Antibiotics</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "Benzodiazepines for insomnia, agitation or delirium in people older than 65",
		"intervention_name" : "Benzodiazepines",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Benzodiazepines</intervention_name>\n    <description>Benzodiazepines for insomnia, agitation or delirium in people older than 65</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Patients visiting GP",
		"description" : "Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis",
		"intervention_name" : "Non-steroidal anti-inflammatory drugs",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Non-steroidal anti-inflammatory drugs</intervention_name>\n    <description>Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis</description>\n    <arm_group_label>Patients visiting GP</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Standard Home Exercise Program",
		"description" : "Standard paper-based home exercise program",
		"intervention_name" : "Standard Home Exercise Program",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Standard Home Exercise Program</intervention_name>\n    <description>Standard paper-based home exercise program</description>\n    <arm_group_label>Standard Home Exercise Program</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.32",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "BAY1093884 in subjects with Hemophilia",
		"description" : "0.3 mg/kg given intravenously",
		"intervention_name" : "BAY1093884",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BAY1093884</intervention_name>\n    <description>0.3 mg/kg given intravenously</description>\n    <arm_group_label>BAY1093884 in subjects with Hemophilia</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sham - Remote Ischemic Conditioning",
		"description" : "Sham Comparator (Sham-RIC)",
		"intervention_name" : "Sham Remote Ischemic Conditioning",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Sham Remote Ischemic Conditioning</intervention_name>\n    <description>Sham Comparator (Sham-RIC)</description>\n    <arm_group_label>Sham - Remote Ischemic Conditioning</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Web-based Home Exercise Program",
		"description" : "Home exercises that are guided by a web-based program",
		"intervention_name" : "Web-based Home Exercise Program",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Web-based Home Exercise Program</intervention_name>\n    <description>Home exercises that are guided by a web-based program</description>\n    <arm_group_label>Web-based Home Exercise Program</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "intervention group",
		"description" : "The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:\nCombination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;",
		"intervention_name" : "intervention group",
		"intervention_type" : "Other",
		"other_name" : "pelvic pattern of proprioceptive neuromuscular facilitation",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>intervention group</intervention_name>\n    <description>The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:\nCombination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;</description>\n    <arm_group_label>intervention group</arm_group_label>\n    <other_name>pelvic pattern of proprioceptive neuromuscular facilitation</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Remote Ischemic Conditioning",
		"description" : "RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.",
		"intervention_name" : "Remote Ischemic Conditioning",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Remote Ischemic Conditioning</intervention_name>\n    <description>RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.</description>\n    <arm_group_label>Remote Ischemic Conditioning</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Randomized within-subjects design",
		"intervention_name" : "Alcohol, Ethyl - placebo",
		"intervention_type" : "Other",
		"other_name" : "Placebo",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Alcohol, Ethyl - placebo</intervention_name>\n    <description>Randomized within-subjects design</description>\n    <arm_group_label>Alcohol, placebo</arm_group_label>\n    <arm_group_label>Alcohol, low dose</arm_group_label>\n    <arm_group_label>Alcohol, moderate dose</arm_group_label>\n    <other_name>Placebo</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.",
		"intervention_name" : "custom slippers with perforated synthetic leather cover.",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>custom slippers with perforated synthetic leather cover.</intervention_name>\n    <description>the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.</description>\n    <arm_group_label>Intervention Group</arm_group_label>\n    <arm_group_label>Control group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Ischemic Conditioning",
		"description" : "RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.",
		"intervention_name" : "Ischemic conditioning device",
		"intervention_type" : "Device",
		"other_name" : "Standard medical care",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Ischemic conditioning device</intervention_name>\n    <description>RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.</description>\n    <arm_group_label>Ischemic Conditioning</arm_group_label>\n    <other_name>Standard medical care</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Microdose administration",
		"description" : "Latanoprost ophthalmic solution administered as a microdose spray",
		"intervention_name" : "Latanoprost",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Latanoprost</intervention_name>\n    <description>Latanoprost ophthalmic solution administered as a microdose spray</description>\n    <arm_group_label>Microdose administration</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sham Neuro RX Gamma device",
		"description" : "Twenty minute treatment session, 6 days a week for 24 weeks",
		"intervention_name" : "Sham Neuro RX Gamma device",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Sham Neuro RX Gamma device</intervention_name>\n    <description>Twenty minute treatment session, 6 days a week for 24 weeks</description>\n    <arm_group_label>Sham Neuro RX Gamma device</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "The exposure variable will be status of the Fontan fenestration",
		"intervention_name" : "Fenestration status",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Fenestration status</intervention_name>\n    <description>The exposure variable will be status of the Fontan fenestration</description>\n  </intervention>",
		"xml_id" : "id-intervention-1.22",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "behavioral intervention",
		"description" : "Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.",
		"intervention_name" : "Text Messaging",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Text Messaging</intervention_name>\n    <description>Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.</description>\n    <arm_group_label>behavioral intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Active Neuro RX Gamma device",
		"description" : "Twenty minute treatment session, 6 days a week for 24 weeks",
		"intervention_name" : "Active Neuro RX Gamma device",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Active Neuro RX Gamma device</intervention_name>\n    <description>Twenty minute treatment session, 6 days a week for 24 weeks</description>\n    <arm_group_label>Active Neuro RX Gamma device</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "BAY1093884 in subjects with Hemophilia",
		"description" : "1 mg/kg given intravenously",
		"intervention_name" : "BAY1093884",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>BAY1093884</intervention_name>\n    <description>1 mg/kg given intravenously</description>\n    <arm_group_label>BAY1093884 in subjects with Hemophilia</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "screening and referral",
		"description" : "Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.",
		"intervention_name" : "Provider Referral",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Provider Referral</intervention_name>\n    <description>Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.</description>\n    <arm_group_label>screening and referral</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.23",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Spinach",
		"description" : "A standardized diet with 200g spinach was provided.",
		"intervention_name" : "Spinach",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Spinach</intervention_name>\n    <description>A standardized diet with 200g spinach was provided.</description>\n    <arm_group_label>Spinach</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.41",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Celery",
		"description" : "A standardized diet with 200g celery was provided.",
		"intervention_name" : "Celery",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Celery</intervention_name>\n    <description>A standardized diet with 200g celery was provided.</description>\n    <arm_group_label>Celery</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.42",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "post rehabilitation",
		"description" : "The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.",
		"intervention_name" : "Robotic Functional Rehabilitation system",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Robotic Functional Rehabilitation system</intervention_name>\n    <description>The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.</description>\n    <arm_group_label>post rehabilitation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.24",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Control",
		"description" : "A standardized diet without any vegetables was provided.",
		"intervention_name" : "Control",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Control</intervention_name>\n    <description>A standardized diet without any vegetables was provided.</description>\n    <arm_group_label>Control</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.40",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Tai-chi intervention",
		"description" : "Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.",
		"intervention_name" : "Tai-Chi",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Tai-Chi</intervention_name>\n    <description>Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.</description>\n    <arm_group_label>Tai-chi intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a \"healthy level\" while the second \"unhealthy.\" Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables.",
		"intervention_name" : "Four FOP label designs",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Four FOP label designs</intervention_name>\n    <description>Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a \"healthy level\" while the second \"unhealthy.\" Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables.</description>\n    <arm_group_label>Uninstructed Group</arm_group_label>\n    <arm_group_label>Minimally trained</arm_group_label>\n    <other_name>color plus facial icon</other_name>\n    <other_name>no color plus facial icon</other_name>\n    <other_name>color plus no facial icon</other_name>\n    <other_name>no color plus no facial icon</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Naltrexone Hydrochloride",
		"description" : "A placebo tablet which matches the drug will be taken daily for 6 weeks.",
		"intervention_name" : "Placebo Comparator",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo Comparator</intervention_name>\n    <description>A placebo tablet which matches the drug will be taken daily for 6 weeks.</description>\n    <arm_group_label>Naltrexone Hydrochloride</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Exercise intervention",
		"description" : "Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.",
		"intervention_name" : "Exercise",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Exercise</intervention_name>\n    <description>Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.</description>\n    <arm_group_label>Exercise intervention</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Dental prophylaxis + aPDT",
		"description" : "Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.",
		"intervention_name" : "Antimicrobial photodynamic therapy (aPDT)",
		"intervention_type" : "Device",
		"other_name" : "Dental prophylaxis + aPDT",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Antimicrobial photodynamic therapy (aPDT)</intervention_name>\n    <description>Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.</description>\n    <arm_group_label>Dental prophylaxis + aPDT</arm_group_label>\n    <other_name>Dental prophylaxis + aPDT</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Randomized within-subjects design",
		"intervention_name" : "Alcohol, Ethyl",
		"intervention_type" : "Drug",
		"other_name" : "Alcohol",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Alcohol, Ethyl</intervention_name>\n    <description>Randomized within-subjects design</description>\n    <arm_group_label>Alcohol, placebo</arm_group_label>\n    <arm_group_label>Alcohol, low dose</arm_group_label>\n    <arm_group_label>Alcohol, moderate dose</arm_group_label>\n    <other_name>Alcohol</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Cycling Cadence Modulation",
		"description" : "6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.",
		"intervention_name" : "Cycling Cadence Modulation",
		"intervention_type" : "Behavioral",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Behavioral</intervention_type>\n    <intervention_name>Cycling Cadence Modulation</intervention_name>\n    <description>6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.</description>\n    <arm_group_label>Cycling Cadence Modulation</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.37",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.",
		"intervention_name" : "Dental prophylaxis",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Dental prophylaxis</intervention_name>\n    <description>Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.</description>\n    <arm_group_label>Dental prophylaxis</arm_group_label>\n    <arm_group_label>Dental prophylaxis + aPDT</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Active rTMS",
		"description" : "10 Hz (2,000 pulses) at left dorsolateral prefrontal cortex",
		"intervention_name" : "Magstim Super Rapid2 stimulator, Active condition",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Magstim Super Rapid2 stimulator, Active condition</intervention_name>\n    <description>10 Hz (2,000 pulses) at left dorsolateral prefrontal cortex</description>\n    <arm_group_label>Active rTMS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Sham rTMS",
		"description" : "sham",
		"intervention_name" : "Magstim Super Rapid2 stimulator, Sham condition",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>Magstim Super Rapid2 stimulator, Sham condition</intervention_name>\n    <description>sham</description>\n    <arm_group_label>Sham rTMS</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Onion",
		"description" : "A standardized diet with 200g onion was provided.",
		"intervention_name" : "Onion",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Onion</intervention_name>\n    <description>A standardized diet with 200g onion was provided.</description>\n    <arm_group_label>Onion</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.43",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Mixed Vegetables",
		"description" : "A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.",
		"intervention_name" : "Mixed Vegetables",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Mixed Vegetables</intervention_name>\n    <description>A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.</description>\n    <arm_group_label>Mixed Vegetables</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.44",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "PAO",
		"description" : "Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.",
		"intervention_name" : "PAO without hip arthroscopy",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>PAO without hip arthroscopy</intervention_name>\n    <description>Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.</description>\n    <arm_group_label>PAO</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.29",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "after group",
		"description" : "mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)",
		"intervention_name" : "mathematical model",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>mathematical model</intervention_name>\n    <description>mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)</description>\n    <arm_group_label>after group</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.31",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Participants receive different monosaccharides for a defined number of days.",
		"intervention_name" : "Dietary Intervention",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Dietary Intervention</intervention_name>\n    <description>Participants receive different monosaccharides for a defined number of days.</description>\n    <arm_group_label>Monosaccharide 1</arm_group_label>\n    <arm_group_label>Monosaccharide 2</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.30",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Scope-PAO",
		"description" : "Participants who are randomized to the PAO group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.",
		"intervention_name" : "PAO with hip arthroscopy",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>PAO with hip arthroscopy</intervention_name>\n    <description>Participants who are randomized to the PAO group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.</description>\n    <arm_group_label>Scope-PAO</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Use of an imaging catheter",
		"intervention_name" : "diagnostic imaging",
		"intervention_type" : "Device",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Device</intervention_type>\n    <intervention_name>diagnostic imaging</intervention_name>\n    <description>Use of an imaging catheter</description>\n    <arm_group_label>IVUS catheter</arm_group_label>\n    <arm_group_label>OCT catheter</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.",
		"intervention_name" : "Assessment & Treatment of HCV infection with oral antivirals",
		"intervention_type" : "Procedure",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Procedure</intervention_type>\n    <intervention_name>Assessment &amp; Treatment of HCV infection with oral antivirals</intervention_name>\n    <description>This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.</description>\n    <arm_group_label>Pharmacist-Led Pathway</arm_group_label>\n    <arm_group_label>Conventional Care Pathway</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "CPI-1205 Combination with Enzalutamide",
		"description" : "Administered orally",
		"intervention_name" : "Enzalutamide",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Enzalutamide</intervention_name>\n    <description>Administered orally</description>\n    <arm_group_label>CPI-1205 Combination with Enzalutamide</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.34",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "CPI-1205 Combination with Abiraterone/Prednisone",
		"description" : "Administered orally",
		"intervention_name" : "Abiraterone/Prednisone",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Abiraterone/Prednisone</intervention_name>\n    <description>Administered orally</description>\n    <arm_group_label>CPI-1205 Combination with Abiraterone/Prednisone</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.35",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Tramadol-Paracetamol",
		"description" : "Paracetamol iv",
		"intervention_name" : "Paracetamol",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Paracetamol</intervention_name>\n    <description>Paracetamol iv</description>\n    <arm_group_label>Tramadol-Paracetamol</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.26",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo Comparator",
		"description" : "Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks to see if it improves in physical health.",
		"intervention_name" : "Naltrexone Hydrochloride",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Naltrexone Hydrochloride</intervention_name>\n    <description>Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks to see if it improves in physical health.</description>\n    <arm_group_label>Placebo Comparator</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.36",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Placebo",
		"description" : "Isotonic saline",
		"intervention_name" : "Placebo",
		"intervention_type" : "Other",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Other</intervention_type>\n    <intervention_name>Placebo</intervention_name>\n    <description>Isotonic saline</description>\n    <arm_group_label>Placebo</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.28",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "Tramadol iv",
		"intervention_name" : "Tramadol",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Tramadol</intervention_name>\n    <description>Tramadol iv</description>\n    <arm_group_label>Tramadol</arm_group_label>\n    <arm_group_label>Tramadol-Paracetamol</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"description" : "All groups with receive standard parenteral (IV) prophylactic antibiotic.",
		"intervention_name" : "intravenous (IV) prophylactic antibiotic",
		"intervention_type" : "Drug",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>intravenous (IV) prophylactic antibiotic</intervention_name>\n    <description>All groups with receive standard parenteral (IV) prophylactic antibiotic.</description>\n    <arm_group_label>topical irrigation with the antibiotic bacitracin</arm_group_label>\n    <arm_group_label>topical irrigation with sterile normal saline (NS)</arm_group_label>\n  </intervention>",
		"xml_id" : "id-intervention-1.25",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	},
	{
		"json_featuretype" : "intervention",
		"arm_group_label" : "Calcitonin gene-related peptide",
		"description" : "Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)",
		"intervention_name" : "Calcitonin Gene-Related Peptide",
		"intervention_type" : "Drug",
		"other_name" : "CGRP",
		"xml_fragment" : "﻿<?xml version=\"1.0\" encoding=\"UTF-16\"?><intervention>\n    <intervention_type>Drug</intervention_type>\n    <intervention_name>Calcitonin Gene-Related Peptide</intervention_name>\n    <description>Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)</description>\n    <arm_group_label>Calcitonin gene-related peptide</arm_group_label>\n    <other_name>CGRP</other_name>\n  </intervention>",
		"xml_id" : "id-intervention-1.27",
		"xml_matched_element" : "intervention",
		"xml_parent_child_pos" : "",
		"xml_parent_id" : ""
	}
]